<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PeerJ</journal-id><journal-id journal-id-type="iso-abbrev">PeerJ</journal-id><journal-id journal-id-type="publisher-id">peerj</journal-id><journal-title-group><journal-title>PeerJ</journal-title></journal-title-group><issn pub-type="epub">2167-8359</issn><publisher><publisher-name>PeerJ Inc.</publisher-name><publisher-loc>San Diego, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12103165</article-id><article-id pub-id-type="publisher-id">19319</article-id><article-id pub-id-type="doi">10.7717/peerj.19319</article-id><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Oncology</subject></subj-group><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group><subj-group subj-group-type="heading"><subject>Women&#x02019;s Health</subject></subj-group></article-categories><title-group><article-title>Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy</article-title></title-group><contrib-group><contrib id="author-1" contrib-type="author"><name><surname>Hutajulu</surname><given-names>Susanna Hilda</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-2" contrib-type="author"><name><surname>Astari</surname><given-names>Yufi Kartika</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib id="author-3" contrib-type="author"><name><surname>Ucche</surname><given-names>Meita</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib id="author-4" contrib-type="author" corresp="yes"><name><surname>Kertia</surname><given-names>Nyoman</given-names></name><email>nyoman.kertia@ugm.ac.id</email><xref rid="aff-4" ref-type="aff">4</xref></contrib><contrib id="author-5" contrib-type="author"><name><surname>Subronto</surname><given-names>Yanri Wijayanti</given-names></name><xref rid="aff-5" ref-type="aff">5</xref></contrib><contrib id="author-6" contrib-type="author"><name><surname>Paramita</surname><given-names>Dewi Kartikawati</given-names></name><xref rid="aff-6" ref-type="aff">6</xref></contrib><contrib id="author-7" contrib-type="author"><name><surname>Choridah</surname><given-names>Lina</given-names></name><xref rid="aff-7" ref-type="aff">7</xref></contrib><contrib id="author-8" contrib-type="author"><name><surname>Ekaputra</surname><given-names>Ericko</given-names></name><xref rid="aff-8" ref-type="aff">8</xref></contrib><contrib id="author-9" contrib-type="author"><name><surname>Widodo</surname><given-names>Irianiwati</given-names></name><xref rid="aff-9" ref-type="aff">9</xref></contrib><contrib id="author-10" contrib-type="author"><name><surname>Suwardjo</surname><given-names>Suwardjo</given-names></name><xref rid="aff-10" ref-type="aff">10</xref></contrib><contrib id="author-11" contrib-type="author"><name><surname>Hardianti</surname><given-names>Mardiah Suci</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-12" contrib-type="author"><name><surname>Taroeno-Hariadi</surname><given-names>Kartika Widayati</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-13" contrib-type="author"><name><surname>Purwanto</surname><given-names>Ibnu</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-14" contrib-type="author"><name><surname>Kurnianda</surname><given-names>Johan</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><aff id="aff-1"><label>1</label><institution>Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-2"><label>2</label><institution>Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-3"><label>3</label><institution>Study Program of Subspecialty, Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-4"><label>4</label><institution>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country> Indonesia</country></aff><aff id="aff-5"><label>5</label><institution>Division of Tropical Medicine and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-6"><label>6</label><institution>Department of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-7"><label>7</label><institution>Division of Radiodiagnosis, Department of Radiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-8"><label>8</label><institution>Division of Radiotherapy, Department of Radiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-9"><label>9</label><institution>Department of Anatomical Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff><aff id="aff-10"><label>10</label><institution>Division of Surgical Oncology, Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital</institution>, <city>Sleman</city>, <state>Yogyakarta Special Region</state>, <country>Indonesia</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Samuel</surname><given-names>Stephen</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year iso-8601-date="2025">2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>e19319</elocation-id><history><date date-type="received" iso-8601-date="2024-12-11"><day>11</day><month>12</month><year iso-8601-date="2024">2024</year></date><date date-type="accepted" iso-8601-date="2025-03-24"><day>24</day><month>3</month><year iso-8601-date="2025">2025</year></date></history><permissions><copyright-statement>&#x000a9;2025 Hutajulu et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Hutajulu et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license></permissions><self-uri xlink:href="https://peerj.com/articles/19319"/><abstract><sec><title>Background</title><p>Breast cancer patients with similar clinicopathologic characteristics may experience varied outcomes. This urges an increased effort to investigate other prognostic factors. C-reactive protein (CRP)-to-albumin ratio (CAR) is an inflammatory and nutritional biomarker that has been well studied and reported to have an impact on the survival of patients with diverse types of cancer, but limitedly in breast cancer. Therefore, this study aimed to investigate the prognostic significance of CAR in local patients with breast cancer.</p></sec><sec><title>Methods</title><p>This study included 202 stage I&#x02013;IV breast cancer patients receiving first-line chemotherapy. We calculated inflammatory and nutritional biomarkers including CAR, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV), and prognostic nutrition index (PNI) before treatment. The Kaplan-Meier with log-rank test and Cox proportional hazard regression were used to analyze the prognostic role of clinicopathologic factors and biomarkers on disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS).</p></sec><sec><title>Results</title><p>The median follow-up period was 46 months (1&#x02013;77 months). The 3-year DFS and 3-year OS in patients with high CAR (CAR &#x0003e; 1.5) were significantly lower than those with low CAR (CAR &#x02264; 1.5) (47.0% <italic toggle="yes">vs</italic> 68.9%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.022 and 59.5% <italic toggle="yes">vs</italic> 78.6%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.009, respectively). Multivariate analysis showed high CAR as prognostic factors for poor DFS (HR 2.10, 95% confidence interval/CI [1.10&#x02013;3.99], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.023) and OS (HR 2.16, 95% CI [1.27&#x02013;3.68], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.005), but not for PFS (HR 1.43, 95% CI [0.73&#x02013;2.80], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.293). In addition, more advanced stage and HER2 positive were correlated with unfavorable DFS and OS, older age predicted poor DFS, and stage was the only prognostic factor of PFS (all <italic toggle="yes">P</italic> values &#x0003c; 0.05).</p></sec><sec><title>Conclusion</title><p>Besides age, stage, and molecular subtypes that have been widely observed to have impact on the survival of breast cancer patients, CAR was demonstrated as a promising prognostic marker in our local patients. A high CAR at diagnosis was associated with unfavorable DFS and OS, which can aid in identifying patients at risk and guide personalized treatment planning.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Breast neoplasms</kwd><kwd>C-reactive protein</kwd><kwd>Albumin</kwd><kwd>Survival</kwd><kwd>Mortality</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>Academic Excellence grant from Universitas Gadjah Mada</funding-source><award-id>4344/UN1/DITLIT/PT.01.03/2024</award-id></award-group><funding-statement>This work was supported by Academic Excellence grant from Universitas Gadjah Mada (grant number: 4344/UN1/DITLIT/PT.01.03/2024). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Breast cancer is the most prevalent malignancy with 66,271 new cases in Indonesia based on GLOBOCAN 2022 data. This cancer accounted for 30.1% of malignancy among women and its mortality ranked third (9.3%) after lung and liver cancer (<xref rid="ref-8" ref-type="bibr">Ferlay et al., 2024</xref>) in both sexes. The 5-year survival was only 51% across all stages and 71% among stage III disease (<xref rid="ref-35" ref-type="bibr">Sinaga et al., 2018</xref>; <xref rid="ref-7" ref-type="bibr">Deanasa, Umar &#x00026; Fitri, 2022</xref>). Breast cancer survival is affected by classic prognostic factors including tumor size, tumor grade, axillary lymph node involvement, disease stage, estrogen receptor (ER) status, and human epidermal growth factor receptor 2 (HER2) overexpression (<xref rid="ref-11" ref-type="bibr">Galea et al., 1992</xref>; <xref rid="ref-12" ref-type="bibr">Goldhirsch et al., 2005</xref>). However, patients with similar clinicopathologic characteristics may experience varied clinical outcomes. Thus, there is a demand to increase exploration of other prognostic factors in order to enable a more individualized treatment, and eventually improve patient outcomes (<xref rid="ref-37" ref-type="bibr">Susini, Biglia &#x00026; Bounous, 2022</xref>).</p><p>It has been observed that the response of the body to cancer greatly corresponds with inflammation and wound healing, during which inflammatory cells and cytokines in tumors play essential roles in tumor development, progression and immunosuppression (<xref rid="ref-5" ref-type="bibr">Balkwill &#x00026; Mantovani, 2001</xref>). Many inflammatory and nutritional biomarkers were demonstrated as independent prognostic factors in breast cancer, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), C-reactive protein (CRP), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV), prognostic nutrition index (PNI), and CRP-to-albumin ratio (CAR) (<xref rid="ref-42" ref-type="bibr">Zhou et al., 2019</xref>; <xref rid="ref-14" ref-type="bibr">Hua et al., 2020</xref>; <xref rid="ref-34" ref-type="bibr">Savioli et al., 2022</xref>; <xref rid="ref-6" ref-type="bibr">Cheng et al., 2024</xref>; <xref rid="ref-41" ref-type="bibr">Zhang &#x00026; Cheng, 2024</xref>). Among these biomarkers, CAR had the greatest discriminating potential in predicting survival outcomes in various types of malignancies such as colorectal, esophageal, and pancreatic cancer (<xref rid="ref-22" ref-type="bibr">Kim et al., 2020</xref>; <xref rid="ref-27" ref-type="bibr">Matsunaga et al., 2020</xref>; <xref rid="ref-38" ref-type="bibr">Suzuki et al., 2020</xref>). CAR reflects both the inflammatory and nutritional status. C-reactive protein (CRP) is an acute-phase protein produced in the liver, which can promote tumor cell invasion, angiogenesis, and metastasis in the inflammatory milieu. Elevated pre-treatment CRP levels have been observed to correlate with tumor aggressiveness, poor treatment response, and unfavorable outcomes in breast cancer patients (<xref rid="ref-2" ref-type="bibr">Allin et al., 2011</xref>; <xref rid="ref-3" ref-type="bibr">Asegaonkar et al., 2015</xref>). Elevated CRP levels are also linked to lower albumin levels because albumin synthesis rate in the liver is suppressed. Serum albumin is a frequently used nutritional status biomarker where nutritional deficiency impairs immune system, reduces the effectiveness of treatment, and increases the risk of unfavorable outcomes in cancer patients (<xref rid="ref-42" ref-type="bibr">Zhou et al., 2019</xref>).</p><p>Although there is growing evidence of the prognostic role of CAR, particularly in gastrointestinal malignancies (<xref rid="ref-40" ref-type="bibr">Xu et al., 2017</xref>; <xref rid="ref-22" ref-type="bibr">Kim et al., 2020</xref>; <xref rid="ref-27" ref-type="bibr">Matsunaga et al., 2020</xref>; <xref rid="ref-38" ref-type="bibr">Suzuki et al., 2020</xref>), studies in breast cancer are limited (<xref rid="ref-42" ref-type="bibr">Zhou et al., 2019</xref>; <xref rid="ref-26" ref-type="bibr">Liu, Guo &#x00026; Zhang, 2021</xref>). Thus, this study aimed to investigate the relationship of CAR serum level as an inflammatory and nutritional biomarker with the survival of local patients with stage I&#x02013;IV breast cancer.</p></sec><sec sec-type="materials|methods"><title>Materials &#x00026; Methods</title><sec><title>Study design and participants</title><p>This retrospective cohort study was authorised by the Medical and Health Research and Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada (reference number: KE/FK/0417/EC/2018). Each participant provided written and signed informed consent before study enrolment. From July 2018 to March 2022, women with breast cancer undergoing first-line chemotherapy, either on adjuvant, neoadjuvant, or palliative setting, in the Hematology and Medical Oncology Division, &#x0201c;Tulip&#x0201d;/Integrated Cancer Clinic, Dr Sardjito General Hospital Yogyakarta, were included in this study. Patients who were enrolled in the study had been pathologically diagnosed with stage I&#x02013;IV breast cancer, aged not less than 18&#x000a0;years, had an Eastern Cooperative Oncology Group (ECOG) performance status of &#x02264;2, without any history of previous chemotherapy, and terminal illness. Patient was excluded if she failed to receive chemotherapy and had not reached the three-year follow-up duration.</p><p>Patients with stage I&#x02013;III breast cancer were assigned to locoregional treatment followed by adjuvant chemotherapy, except for patients considered to receive pre-operative or neoadjuvant chemotherapy. Candidates for neoadjuvant chemotherapy included inflammatory breast cancer, cT4 tumor, cN3 nodal disease, or HER2-positive and triple-negative breast cancer with &#x02265;cT2 or &#x02265;cN1. Patients with stage IV breast cancer were assigned to receive locoregional treatment and/or palliative chemotherapy (<xref rid="ref-13" ref-type="bibr">Gradishar et al., 2024</xref>). The chemotherapy regimen for adjuvant and neoadjuvant setting was anthracycline (doxorubicin or epirubicin) and cyclophosphamide followed by taxane (docetaxel or paclitaxel) every 3 weeks. The chemotherapy regimen for palliative setting was taxane, as monotherapy or in combination with carboplatin, or capecitabine. The endpoints of this study were disease-free survival (DFS) for patients receiving adjuvant chemotherapy, progression-free survival (PFS) for patients receiving neoadjuvant or palliative chemotherapy, and overall survival (OS) for all included participants.</p><p>Of the 250 eligible patients, 48 were excluded because they did not receive chemotherapy (<italic toggle="yes">n</italic> = 36) or the follow-up duration had not reached 3&#x000a0;years (<italic toggle="yes">n</italic> = 12). A total of 202 patients with stage I&#x02013;IV breast cancer were included in the study and later in the OS analysis. One hundred and twenty-nine patients received adjuvant chemotherapy and were included in the DFS analysis. Seventy-three patients received neoadjuvant and palliative chemotherapy and were included in the PFS analysis (<xref rid="fig-1" ref-type="fig">Fig. 1</xref>).</p><fig position="float" id="fig-1"><object-id pub-id-type="doi">10.7717/peerj.19319/fig-1</object-id><label>Figure 1</label><caption><title>Flowchart of subject&#x02019;s inclusion to the study and final analysis.</title></caption><graphic xlink:href="peerj-13-19319-g001" position="float"/></fig></sec><sec><title>Data collection and definition</title><p>Patient clinical and pathological data collection included age at diagnosis (&#x0003c;50 years <italic toggle="yes">vs</italic> &#x02265;50 years), the tumor, nodes, metastasis (TNM) stage according to the criteria of the American Joint Committee on Cancer (AJCC) 8th edition, the estrogen receptors (ER), progesterone receptors (PR), and HER2 status (negative <italic toggle="yes">vs</italic> positive), and the chemotherapy intention (adjuvant, neoadjuvant, or palliative). The complete blood cell count, including neutrophil (/&#x000b5;l), lymphocyte (/&#x000b5;l), monocyte (/&#x000b5;l), and platelet (/&#x000b5;l) counts, as well as serum albumin (g/dl) were routinely measured for each patient. In addition, 21 ml peripheral blood samples were obtained before the first chemotherapy cycle. After centrifugation, plasma samples were aliquoted and stored at &#x02212;80&#x000a0;&#x000b0;C in Biobank, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada. CRP serum levels were analyzed using a quantitative Enzyme-linked Immunosorbent Assay (ELISA) (Calbiotech, El Cajon, California, Catalog No. CR120C) in the Integrated Research laboratory, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada by trained laboratory staff. Thus, with the collected laboratory data, we analyzed inflammation and nutritional biomarkers including NLR, PLR, LMR, SII, SIRI, PIV, PNI, and CAR. Each biomarker&#x02019;s definition and formula were described in <xref rid="table-1" ref-type="table">Table 1</xref>.</p></sec><sec><title>Cut-off values for inflammatory and nutritional biomarkers</title><p>We performed receiver operating curve (ROC) analysis to determine optimal cut-off levels of all biomarkers using the Liu method (<xref rid="ref-25" ref-type="bibr">Liu, 2012</xref>). DFS, PFS, and OS rates are the most appropriate measures of prognosis. Considering it is unusual to designate more than one cut-off level in the same biomarker, we chose a 3-year OS as a stratifying point. Determined optimal cut-offs of NLR, PLR, LMR, SII, SIRI, PIV, PNI, and CAR were 1.995, 145.5, 0.265, 774.8, 1.11, 331.8, 54.06, and 1.5, respectively (<xref rid="table-2" ref-type="table">Table 2</xref>). Patients were further grouped based on these cut-off values.</p><p>To evaluate the biomarker&#x02019;s predictive ability, we measured and compared the area under the ROC curve (AUC) of each biomarker. Among all inflammatory and nutritional biomarkers, CAR showed the highest AUC of 0.608 (<xref rid="table-2" ref-type="table">Table 2</xref>). Thus, patients&#x02019; baseline characteristics were further compared between CAR groups. Patients with CAR &#x02264;1.5 were grouped as low CAR and patients with CAR &#x0003e;1.5 were grouped as high CAR.</p></sec><sec><title>Follow-up</title><p>All study participants underwent three-monthly follow-up after chemotherapy for the first year, and every six months afterwards. Follow-up included clinical examination, laboratory tests, breast ultrasonography, abdominal ultrasonography, chest X-ray, bone survey or bone scan, and other examinations as deemed appropriate. The final follow-up ended on August 2024, through medical records and telephone follow-up. DFS and PFS were referred to the time from pathological diagnosis to the first detection of local recurrence, disease progression, or death, or to the last follow-up. OS was defined as the time from pathological diagnosis to death from any cause or to the last follow-up.</p><table-wrap position="float" id="table-1"><object-id pub-id-type="doi">10.7717/peerj.19319/table-1</object-id><label>Table 1</label><caption><title>Eight biomarkers evaluated in this study.</title></caption><alternatives><graphic xlink:href="peerj-13-19319-g004" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<bold>Biomarker&#x02019;s name</bold>
</th><th rowspan="1" colspan="1">
<bold>Biomarker&#x02019;s formula</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Neutrophil-to-lymphocyte ratio (NLR)</td><td rowspan="1" colspan="1">Neutrophil/lymphocyte</td></tr><tr><td rowspan="1" colspan="1">Platelet-to-lymphocyte ratio (PLR)</td><td rowspan="1" colspan="1">Platelet/lymphocyte</td></tr><tr><td rowspan="1" colspan="1">Lymphocyte-to-monocyte ratio (LMR)</td><td rowspan="1" colspan="1">Lymphocyte/monocyte</td></tr><tr><td rowspan="1" colspan="1">Systemic immune-inflammation index (SII)</td><td rowspan="1" colspan="1">Neutrophil&#x000a0;&#x000d7;&#x000a0;platelet/lymphocyte</td></tr><tr><td rowspan="1" colspan="1">Systemic inflammation response index (SIRI)</td><td rowspan="1" colspan="1">Neutrophil&#x000a0;&#x000d7;&#x000a0;monocyte/lymphocyte</td></tr><tr><td rowspan="1" colspan="1">Pan-immune-inflammation value (PIV)</td><td rowspan="1" colspan="1">Neutrophil&#x000a0;&#x000d7;&#x000a0;platelet&#x000a0;&#x000d7;&#x000a0;monocyte/lymphocyte</td></tr><tr><td rowspan="1" colspan="1">Prognostic nutrition index (PNI)</td><td rowspan="1" colspan="1">(10&#x000a0;&#x000d7;&#x000a0;Albumin) + (0.005&#x000a0;&#x000d7;&#x000a0;lymphocyte)</td></tr><tr><td rowspan="1" colspan="1">CRP-to-albumin ratio (CAR)</td><td rowspan="1" colspan="1">CRP/albumin</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-1fn"><p>
<bold>Notes.</bold>
</p></fn><fn id="table-1fn1" fn-type="other"><p>
<def-list id="dl1"><def-item><term> CRP</term><def><p>C-reactive protein</p></def></def-item></def-list>
</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="table-2"><object-id pub-id-type="doi">10.7717/peerj.19319/table-2</object-id><label>Table 2</label><caption><title>Comparison of area under curve (AUC) of evaluated biomarkers for overall survival.</title></caption><alternatives><graphic xlink:href="peerj-13-19319-g005" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<bold>Biomarkers</bold>
</th><th rowspan="1" colspan="1">
<bold>Cut-off</bold>
</th><th rowspan="1" colspan="1">
<bold>AUC</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">NLR</td><td rowspan="1" colspan="1">1.995</td><td rowspan="1" colspan="1">0.513</td><td rowspan="1" colspan="1">0.43&#x02013;0.59</td></tr><tr><td rowspan="1" colspan="1">PLR</td><td rowspan="1" colspan="1">145.5</td><td rowspan="1" colspan="1">0.473</td><td rowspan="1" colspan="1">0.39&#x02013;0.56</td></tr><tr><td rowspan="1" colspan="1">LMR</td><td rowspan="1" colspan="1">0.265</td><td rowspan="1" colspan="1">0.576</td><td rowspan="1" colspan="1">0.49&#x02013;0.66</td></tr><tr><td rowspan="1" colspan="1">SII</td><td rowspan="1" colspan="1">774.8</td><td rowspan="1" colspan="1">0.465</td><td rowspan="1" colspan="1">0.38&#x02013;0.55</td></tr><tr><td rowspan="1" colspan="1">SIRI</td><td rowspan="1" colspan="1">1.11</td><td rowspan="1" colspan="1">0.475</td><td rowspan="1" colspan="1">0.39&#x02013;0.56</td></tr><tr><td rowspan="1" colspan="1">PIV</td><td rowspan="1" colspan="1">331.8</td><td rowspan="1" colspan="1">0.490</td><td rowspan="1" colspan="1">0.40&#x02013;0.57</td></tr><tr><td rowspan="1" colspan="1">PNI</td><td rowspan="1" colspan="1">54.06</td><td rowspan="1" colspan="1">0.561</td><td rowspan="1" colspan="1">0.48&#x02013;0.64</td></tr><tr><td rowspan="1" colspan="1">CAR</td><td rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">0.608</td><td rowspan="1" colspan="1">0.52&#x02013;0.69</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-2fn"><p>
<bold>Notes.</bold>
</p></fn><fn id="table-2fn1" fn-type="other"><p>
<def-list id="dl2"><def-item><term> CI</term><def><p>confidence interval</p></def></def-item><def-item><term> NLR</term><def><p>neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term> PLR</term><def><p>platelet-to-lymphocyte ratio</p></def></def-item><def-item><term> LMR</term><def><p>lymphocyte-to-monocyte ratio</p></def></def-item><def-item><term> SII</term><def><p>systemic immune-inflammation index</p></def></def-item><def-item><term> SIRI</term><def><p>systemic inflammation response index</p></def></def-item><def-item><term> PIV</term><def><p>pan-immune inflammation value</p></def></def-item><def-item><term> PNI</term><def><p>prognostic nutritional index</p></def></def-item><def-item><term> CAR</term><def><p>C-reactive protein-to-albumin ratio</p></def></def-item></def-list>
</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Statistical analysis</title><p>The categorical variables were presented as frequencies with percentages and the numerical variables were presented as median with interquartile range (IQR). The survival status was estimated using the Kaplan&#x02013;Meier curves with log-rank test. Clinicopathological factors and biomarkers associated with survival outcomes were analyzed using univariate and multivariate Cox proportional hazard regression. Clinicopathological factors and biomarkers with <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 in the univariate analysis and variable of interest in this current study, CAR, were entered into multivariate analysis for DFS, PFS, and OS. A <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 was considered statistically significant. The statistical analyses were performed with STATA version 17 (Stata Corp., College Station, TX).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Baseline characteristics</title><p>The median age was 51 years (IQR 45.4&#x02013;57.6 years). Most of patients were diagnosed with stage III breast cancer (42.1%), with ER positive (61.9%), and HER2 negative (67.3%). Compared between the low CAR and high CAR groups, patients&#x02019; baseline characteristics showed significant differences in terms of stage and chemotherapy intention. High CAR was more frequent in patients with stage IV (35.5% <italic toggle="yes">vs</italic> 12.5%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.002), those receiving neoadjuvant treatment, and those receiving palliative chemotherapy (10.5% <italic toggle="yes">vs</italic> 6.8% and 35.5% <italic toggle="yes">vs</italic> 12.5%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.001) (<xref rid="table-3" ref-type="table">Table 3</xref>).</p><table-wrap position="float" id="table-3"><object-id pub-id-type="doi">10.7717/peerj.19319/table-3</object-id><label>Table 3</label><caption><title>Baseline characteristics of the subjects included in the study by CAR status.</title></caption><alternatives><graphic xlink:href="peerj-13-19319-g006" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<bold>Characteristics</bold>
</th><th rowspan="1" colspan="1"><bold>All subjects</bold><break/>(<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;202)</th><th rowspan="1" colspan="1"><bold>CAR &#x02264;1.5</bold><break/>(<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;88)</th><th rowspan="1" colspan="1"><bold>CAR &#x0003e;&#x000a0;1.5</bold><break/>(<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;76)</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (Median (IQR))</td><td rowspan="1" colspan="1">51.3 (45.4&#x02013;57.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;50 years</td><td rowspan="1" colspan="1">73 (44.5)</td><td rowspan="1" colspan="1">45 (51.1)</td><td rowspan="1" colspan="1">28 (36.8)</td><td rowspan="1" colspan="1">0.066</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;50 years</td><td rowspan="1" colspan="1">91 (55.5)</td><td rowspan="1" colspan="1">43 (48.9)</td><td rowspan="1" colspan="1">48 (63.2)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">I&#x02013;II</td><td rowspan="1" colspan="1">60 (29.7)</td><td rowspan="1" colspan="1">30 (34.1)</td><td rowspan="1" colspan="1">20 (26.3)</td><td rowspan="1" colspan="1">0.002</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">85 (42.1)</td><td rowspan="1" colspan="1">47 (53.4)</td><td rowspan="1" colspan="1">29 (38.2)</td><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">IV</td><td rowspan="1" colspan="1">57 (28.2)</td><td rowspan="1" colspan="1">11 (12.5)</td><td rowspan="1" colspan="1">27 (35.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">ER</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">74 (36.6)</td><td rowspan="1" colspan="1">35 (39.8)</td><td rowspan="1" colspan="1">27 (35.5)</td><td rowspan="1" colspan="1">0.576</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">125 (61.9)</td><td rowspan="1" colspan="1">53 (60.2)</td><td rowspan="1" colspan="1">49 (64.5)</td><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">3 (1.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">93 (46.0)</td><td rowspan="1" colspan="1">45 (51.1)</td><td rowspan="1" colspan="1">33 (43.4)</td><td rowspan="1" colspan="1">0.324</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">106 (52.5)</td><td rowspan="1" colspan="1">43 (48.9)</td><td rowspan="1" colspan="1">43 (56.6)</td><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">3 (1.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">HER2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">136 (67.3)</td><td rowspan="1" colspan="1">57 (66.3)</td><td rowspan="1" colspan="1">52 (69.3)</td><td rowspan="1" colspan="1">0.679</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">60 (29.7)</td><td rowspan="1" colspan="1">29 (33.7)</td><td rowspan="1" colspan="1">23 (30.7)</td><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">6 (3.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Biomarkers (Median (IQR))</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">NLR</td><td rowspan="1" colspan="1">2.48 (1.78&#x02013;3.47)</td><td rowspan="1" colspan="1">2.41 (1.70&#x02013;3.46)</td><td rowspan="1" colspan="1">2.47 (1.84&#x02013;3.35)</td><td rowspan="1" colspan="1">0.984</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">PLR</td><td rowspan="1" colspan="1">157 (117&#x02013;214)</td><td rowspan="1" colspan="1">161 (124&#x02013;208)</td><td rowspan="1" colspan="1">143 (112&#x02013;207)</td><td rowspan="1" colspan="1">0.164</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">LMR</td><td rowspan="1" colspan="1">0.26 (0.20&#x02013;0.36)</td><td rowspan="1" colspan="1">0.26 (0.19&#x02013;0.34)</td><td rowspan="1" colspan="1">0.26 (0.19&#x02013;0.35)</td><td rowspan="1" colspan="1">0.796</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">SII</td><td rowspan="1" colspan="1">720 (494&#x02013;1075)</td><td rowspan="1" colspan="1">681 (472&#x02013;1025)</td><td rowspan="1" colspan="1">753 (489&#x02013;1087)</td><td rowspan="1" colspan="1">0.582</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">SIRI</td><td rowspan="1" colspan="1">1.20 (0.78&#x02013;1.73)</td><td rowspan="1" colspan="1">1.06 (0.71&#x02013;1.52)</td><td rowspan="1" colspan="1">1.23 (0.82&#x02013;1.74)</td><td rowspan="1" colspan="1">0.202</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">PIV</td><td rowspan="1" colspan="1">325 (211&#x02013;569)</td><td rowspan="1" colspan="1">294 (202&#x02013;538)</td><td rowspan="1" colspan="1">384 (224&#x02013;583)</td><td rowspan="1" colspan="1">0.218</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">PNI (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;191)</td><td rowspan="1" colspan="1">52.8 (47.9&#x02013;56.8)</td><td rowspan="1" colspan="1">53.9 (50.3&#x02013;56.9)</td><td rowspan="1" colspan="1">53.3 (47.9&#x02013;57.4)</td><td rowspan="1" colspan="1">0.388</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">CAR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;164)</td><td rowspan="1" colspan="1">1.23 (0.39&#x02013;2.67)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Chemotherapy intention</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Adjuvant</td><td rowspan="1" colspan="1">129 (63.9)</td><td rowspan="1" colspan="1">71 (80.7)</td><td rowspan="1" colspan="1">41 (54.0)</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Neoadjuvant</td><td rowspan="1" colspan="1">16 (7.9)</td><td rowspan="1" colspan="1">6 (6.8)</td><td rowspan="1" colspan="1">8 (10.5)</td><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Palliative</td><td rowspan="1" colspan="1">57 (28.2)</td><td rowspan="1" colspan="1">11 (12.5)</td><td rowspan="1" colspan="1">27 (35.5)</td><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-3fn"><p>
<bold>Notes.</bold>
</p></fn><fn id="table-3fn1" fn-type="other"><p>
<def-list id="dl3"><def-item><term> IQR</term><def><p>interquartile range</p></def></def-item><def-item><term> ER</term><def><p>estrogen receptors</p></def></def-item><def-item><term> PR</term><def><p>progesterone receptors</p></def></def-item><def-item><term> HER2</term><def><p>human epidermal growth factor receptor 2</p></def></def-item><def-item><term> NLR</term><def><p>neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term> PLR</term><def><p>platelet-to-lymphocyte ratio</p></def></def-item><def-item><term> LMR</term><def><p>lymphocyte-to-monocyte ratio</p></def></def-item><def-item><term> SII</term><def><p>systemic immune-inflammation index</p></def></def-item><def-item><term> SIRI</term><def><p>systemic inflammation response index</p></def></def-item><def-item><term> PIV</term><def><p>pan-immune inflammation value</p></def></def-item><def-item><term> PNI</term><def><p>prognostic nutritional index</p></def></def-item><def-item><term> CAR</term><def><p>C-reactive protein-to-albumin ratio</p></def></def-item></def-list>
</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Patients&#x02019; survival by clinicopathologic factors, inflammatory, and nutritional investigated biomarkers</title><p>Overall, the median follow-up of patients in this study was 46 months (1&#x02013;77 months). The median DFS and PFS were 73.2 and 13.1 months, while the median OS was not reached. The 3-year DFS, PFS, and OS are 62.9%, 16.9%, and 65.7% (<xref rid="fig-2" ref-type="fig">Figs. 2A</xref>&#x02013;<xref rid="fig-2" ref-type="fig">2C</xref>). Kaplan&#x02013;Meier survival curves and log-rank test revealed that cases with advanced stage (stage III or IV) (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.004 and <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), HER2 positive (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001 and <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.023), and high CAR (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.022 and <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.009) had a significantly poorer 3-year DFS (<xref rid="fig-3" ref-type="fig">Figs. 3B</xref>&#x02013;<xref rid="fig-3" ref-type="fig">3D</xref>) and OS (<xref rid="fig-3" ref-type="fig">Figs. 3J</xref>&#x02013;<xref rid="fig-3" ref-type="fig">3L</xref>) compared with their counterparts. In addition, age &#x02265;50 years (<italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) was significantly associated with poorer DFS (<xref rid="fig-3" ref-type="fig">Fig. 3A</xref>). The 3-year DFS and 3-year OS in patients with high CAR were significantly lower than those with low CAR (47.0% <italic toggle="yes">vs</italic> 68.9%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.022 and 59.5% <italic toggle="yes">vs</italic> 78.6%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.009) (<xref rid="fig-3" ref-type="fig">Figs. 3D</xref> and <xref rid="fig-3" ref-type="fig">3L</xref>). Stage was the only parameter related to 3-year PFS in which cases with stage IV disease (<italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.007) had unfavorable survival (<xref rid="fig-3" ref-type="fig">Fig. 3F</xref>). The 3-year PFS of patients with high and low CAR was similar (20.6% <italic toggle="yes">vs</italic> 23.5%, <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.333) (<xref rid="fig-3" ref-type="fig">Fig. 3H</xref>). No significant differences in 3-year DFS, PFS, and OS were observed in cases having different levels of other inflammatory and nutritional biomarkers (<xref rid="supplemental-information" ref-type="sec">Figs. S1</xref>&#x02013;<xref rid="supplemental-information" ref-type="sec">S3</xref>).</p><fig position="float" id="fig-2"><object-id pub-id-type="doi">10.7717/peerj.19319/fig-2</object-id><label>Figure 2</label><caption><title>Breast cancer survival.</title><p>(A) Kaplan&#x02013;Meier curves for disease-free survival (DFS) in 129 breast cancer patients receiving adjuvant chemotherapy. (B) Kaplan&#x02013;Meier curves for progression-free survival (PFS) in 73 breast cancer patients receiving neoadjuvant or palliative chemotherapy. (C) Kaplan&#x02013;Meier curves for overall survival (OS) in 202 breast cancer patients receiving chemotherapy.</p></caption><graphic xlink:href="peerj-13-19319-g002" position="float"/></fig><fig position="float" id="fig-3"><object-id pub-id-type="doi">10.7717/peerj.19319/fig-3</object-id><label>Figure 3</label><caption><title>Relationship between clinicopathological factors and CAR and breast cancer survival.</title><p>(A&#x02013;D) Kaplan&#x02013;Meier curves for 3-year disease-free survival (DFS) based on age, stage, human epidermal receptor 2 (HER2) status, and C-reactive protein to albumin ratio (CAR). (E&#x02013;H) Kaplan Meier curves for 3-year progression-free survival (PFS) based on age, stage, HER2 status, and CAR. (I&#x02013;L) Kaplan Meier curves for 3-year overall survival (OS) based on age, stage, HER2 status, and CAR.</p></caption><graphic xlink:href="peerj-13-19319-g003" position="float"/></fig></sec><sec><title>Prognostic significance of clinicopathologic factors, inflammatory, and nutritional biomarkers</title><p>Analyses of DFS prognostic factors were summarized in <xref rid="table-4" ref-type="table">Table 4</xref>. According to multivariate analysis, high CAR was a prognostic factor for unfavorable DFS (HR 2.10, 95% CI [1.10&#x02013;3.99], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.023). Age (HR 2.32, 95% CI [1.21&#x02013;4.48], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.012), stage (HR 3.07, 95% CI [1.58&#x02013;5.95], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.001), and HER2 status (HR 2.99, 95% CI [1.60&#x02013;5.61], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.001) were also predictors for DFS.</p><table-wrap position="float" id="table-4"><object-id pub-id-type="doi">10.7717/peerj.19319/table-4</object-id><label>Table 4</label><caption><title>Univariate and multivariate analysis predicting disease-free survival (DFS).</title></caption><alternatives><graphic xlink:href="peerj-13-19319-g007" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<bold>Factor</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic>
</bold>
</th><th align="center" colspan="3" rowspan="1">
<bold>Univariate (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;129)</bold>
</th><th align="center" colspan="3" rowspan="1">
<bold>Multivariate ((<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;110)</bold>
</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">
<bold>HR</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th><th rowspan="1" colspan="1">
<bold>HR</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;50 years</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;50 years</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">2.78</td><td rowspan="1" colspan="1">1.53&#x02013;5.04</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">2.32</td><td rowspan="1" colspan="1">1.21&#x02013;4.48</td><td rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">I&#x02013;II</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">72</td><td rowspan="1" colspan="1">2.41</td><td rowspan="1" colspan="1">1.34&#x02013;4.31</td><td rowspan="1" colspan="1">0.003</td><td rowspan="1" colspan="1">3.07</td><td rowspan="1" colspan="1">1.58&#x02013;5.95</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">ER</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">50</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">79</td><td rowspan="1" colspan="1">0.58</td><td rowspan="1" colspan="1">0.34&#x02013;0.99</td><td rowspan="1" colspan="1">0.047</td><td rowspan="1" colspan="1">0.69</td><td rowspan="1" colspan="1">0.37&#x02013;1.30</td><td rowspan="1" colspan="1">0.254</td></tr><tr><td rowspan="1" colspan="1">PR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">61</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">68</td><td rowspan="1" colspan="1">0.65</td><td rowspan="1" colspan="1">0.38&#x02013;1.11</td><td rowspan="1" colspan="1">0.118</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">HER2 (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;127)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">2.54</td><td rowspan="1" colspan="1">1.48&#x02013;4.37</td><td rowspan="1" colspan="1">0.001</td><td rowspan="1" colspan="1">2.99</td><td rowspan="1" colspan="1">1.60&#x02013;5.61</td><td rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1">NLR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.995</td><td rowspan="1" colspan="1">53</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.995</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">0.87</td><td rowspan="1" colspan="1">0.51&#x02013;1.48</td><td rowspan="1" colspan="1">0.607</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PLR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;145.5</td><td rowspan="1" colspan="1">62</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;145.5</td><td rowspan="1" colspan="1">67</td><td rowspan="1" colspan="1">1.07</td><td rowspan="1" colspan="1">0.63&#x02013;1.82</td><td rowspan="1" colspan="1">0.803</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">LMR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;0.265</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;0.265</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">1.45</td><td rowspan="1" colspan="1">0.84&#x02013;2.52</td><td rowspan="1" colspan="1">0.185</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SII</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;774.8</td><td rowspan="1" colspan="1">80</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;774.8</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">0.56&#x02013;1.67</td><td rowspan="1" colspan="1">0.913</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SIRI</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.11</td><td rowspan="1" colspan="1">66</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.11</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">0.67</td><td rowspan="1" colspan="1">0.39&#x02013;1.15</td><td rowspan="1" colspan="1">0.147</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PIV</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;331.8</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;331.8</td><td rowspan="1" colspan="1">58</td><td rowspan="1" colspan="1">0.78</td><td rowspan="1" colspan="1">0.45&#x02013;1.33</td><td rowspan="1" colspan="1">0.355</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PNI (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;120)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;54.06</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;54.06</td><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1">0.67</td><td rowspan="1" colspan="1">0.38&#x02013;1.17</td><td rowspan="1" colspan="1">0.161</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CAR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;112)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.5</td><td rowspan="1" colspan="1">71</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.5</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">1.61</td><td rowspan="1" colspan="1">0.92&#x02013;2.83</td><td rowspan="1" colspan="1">0.097</td><td rowspan="1" colspan="1">2.10</td><td rowspan="1" colspan="1">1.10&#x02013;3.99</td><td rowspan="1" colspan="1">0.023</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-4fn"><p>
<bold>Notes.</bold>
</p></fn><fn id="table-4fn1" fn-type="other"><p>
<def-list id="dl4"><def-item><term> HR</term><def><p>Hazard Ratio</p></def></def-item><def-item><term> CI</term><def><p>confidence interval</p></def></def-item><def-item><term> ER</term><def><p>estrogen receptors</p></def></def-item><def-item><term> PR</term><def><p>progesterone receptors</p></def></def-item><def-item><term> HER2</term><def><p>human epidermal growth factor receptor 2</p></def></def-item><def-item><term> NLR</term><def><p>neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term> PLR</term><def><p>platelet-to-lymphocyte ratio</p></def></def-item><def-item><term> LMR</term><def><p>lymphocyte-to-monocyte ratio</p></def></def-item><def-item><term> SII</term><def><p>systemic immune-inflammation index</p></def></def-item><def-item><term> SIRI</term><def><p>systemic inflammation response index</p></def></def-item><def-item><term> PIV</term><def><p>pan-immune inflammation value</p></def></def-item><def-item><term> PNI</term><def><p>prognostic nutritional index</p></def></def-item><def-item><term> CAR</term><def><p>C-reactive protein-to-albumin ratio</p></def></def-item></def-list>
</p></fn></table-wrap-foot></table-wrap><p>Analyses of PFS prognostic factors were summarized in <xref rid="table-5" ref-type="table">Table 5</xref>. In univariate analysis of PFS, stage was the only significant prognostic factor. The multivariate analysis also showed that stage IV was associated with poor PFS (HR 2.45, 95% CI [1.12&#x02013;5.37], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.025), while CAR was not (HR 1.43, 95% CI [0.73&#x02013;2.80], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.293).</p><table-wrap position="float" id="table-5"><object-id pub-id-type="doi">10.7717/peerj.19319/table-5</object-id><label>Table 5</label><caption><title>Univariate and multivariate analysis predicting progress-free survival (PFS).</title></caption><alternatives><graphic xlink:href="peerj-13-19319-g008" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<bold>Factor</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic>
</bold>
</th><th align="center" colspan="3" rowspan="1">
<bold>Univariate (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;73)</bold>
</th><th align="center" colspan="3" rowspan="1">
<bold>Multivariate (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;52)</bold>
</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">
<bold>HR</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th><th rowspan="1" colspan="1">
<bold>HR</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;50 years</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;50 years</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">0.50&#x02013;1.38</td><td rowspan="1" colspan="1">0.467</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">II&#x02013;III</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">IV</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">2.24</td><td rowspan="1" colspan="1">1.13&#x02013;4.47</td><td rowspan="1" colspan="1">0.021</td><td rowspan="1" colspan="1">2.45</td><td rowspan="1" colspan="1">1.12&#x02013;5.37</td><td rowspan="1" colspan="1">0.025</td></tr><tr><td rowspan="1" colspan="1">ER (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;70)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">0.97</td><td rowspan="1" colspan="1">0.55&#x02013;1.70</td><td rowspan="1" colspan="1">0.922</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;70)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">1.03</td><td rowspan="1" colspan="1">0.60&#x02013;1.74</td><td rowspan="1" colspan="1">0.920</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">HER2 (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;69)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">1.04</td><td rowspan="1" colspan="1">0.59&#x02013;1.82</td><td rowspan="1" colspan="1">0.883</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">NLR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.995</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.995</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">1.14</td><td rowspan="1" colspan="1">0.61&#x02013;2.10</td><td rowspan="1" colspan="1">0.685</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PLR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;145.5</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;145.5</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">1.08</td><td rowspan="1" colspan="1">0.63&#x02013;1.84</td><td rowspan="1" colspan="1">0.773</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">LMR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;0.265</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;0.265</td><td rowspan="1" colspan="1">28</td><td rowspan="1" colspan="1">0.72</td><td rowspan="1" colspan="1">0.42&#x02013;1.23</td><td rowspan="1" colspan="1">0.227</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SII</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;774.8</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;774.8</td><td rowspan="1" colspan="1">42</td><td rowspan="1" colspan="1">1.26</td><td rowspan="1" colspan="1">0.75&#x02013;2.11</td><td rowspan="1" colspan="1">0.385</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SIRI</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.11</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.11</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">1.24</td><td rowspan="1" colspan="1">0.71&#x02013;2.14</td><td rowspan="1" colspan="1">0.447</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PIV</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;331.8</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;331.8</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">1.63</td><td rowspan="1" colspan="1">0.97&#x02013;2.75</td><td rowspan="1" colspan="1">0.066</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PNI (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;70)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;54.06</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;54.06</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">1.25</td><td rowspan="1" colspan="1">0.67&#x02013;2.34</td><td rowspan="1" colspan="1">0.475</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">CAR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;52)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.5</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.5</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">1.48</td><td rowspan="1" colspan="1">0.76&#x02013;2.88</td><td rowspan="1" colspan="1">0.249</td><td rowspan="1" colspan="1">1.43</td><td rowspan="1" colspan="1">0.73&#x02013;2.80</td><td rowspan="1" colspan="1">0.293</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-5fn"><p>
<bold>Notes.</bold>
</p></fn><fn id="table-5fn1" fn-type="other"><p>
<def-list id="dl5"><def-item><term> HR</term><def><p>Hazard Ratio</p></def></def-item><def-item><term> CI</term><def><p>confidence interval</p></def></def-item><def-item><term> ER</term><def><p>estrogen receptors</p></def></def-item><def-item><term> PR</term><def><p>progesterone receptors</p></def></def-item><def-item><term> HER2</term><def><p>human epidermal growth factor receptor 2</p></def></def-item><def-item><term> NLR</term><def><p>neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term> PLR</term><def><p>platelet-to-lymphocyte ratio</p></def></def-item><def-item><term> LMR</term><def><p>lymphocyte-to-monocyte ratio</p></def></def-item><def-item><term> SII</term><def><p>systemic immune-inflammation index</p></def></def-item><def-item><term> SIRI</term><def><p>systemic inflammation response index</p></def></def-item><def-item><term> PIV</term><def><p>pan-immune inflammation value</p></def></def-item><def-item><term> PNI</term><def><p>prognostic nutritional index</p></def></def-item><def-item><term> CAR</term><def><p>C-reactive protein-to-albumin ratio</p></def></def-item></def-list>
</p></fn></table-wrap-foot></table-wrap><p>Analyses of OS prognostic factors were summarized in <xref rid="table-6" ref-type="table">Table 6</xref>. In the univariate and multivariate analysis, high CAR was a prognostic factor of unfavorable OS (HR 2.11, 95% CI [1.24&#x02013;3.57], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.005 and HR 2.16, 95% CI [1.27&#x02013;3.68], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.005). Stage (HR 9.42, 95% CI [2.94&#x02013;30.25], <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and HER2 status (HR 2.05, 95% CI [1.17&#x02013;3.56], <italic toggle="yes">P</italic>&#x000a0;=&#x000a0;0.011) were also independent predictors for OS.</p><table-wrap position="float" id="table-6"><object-id pub-id-type="doi">10.7717/peerj.19319/table-6</object-id><label>Table 6</label><caption><title>Univariate and multivariate analysis predicting overall survival (OS).</title></caption><alternatives><graphic xlink:href="peerj-13-19319-g009" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1">
<bold>Factor</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">n</italic>
</bold>
</th><th align="center" colspan="3" rowspan="1">
<bold>Univariate (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;202)</bold>
</th><th align="center" colspan="3" rowspan="1">
<bold>Multivariate (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;161)</bold>
</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">
<bold>HR</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th><th rowspan="1" colspan="1">
<bold>HR</bold>
</th><th rowspan="1" colspan="1">
<bold>95% CI</bold>
</th><th rowspan="1" colspan="1">
<bold>
<italic toggle="yes">P</italic>
</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;50 years</td><td rowspan="1" colspan="1">92</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;50 years</td><td rowspan="1" colspan="1">110</td><td rowspan="1" colspan="1">1.16</td><td rowspan="1" colspan="1">0.74&#x02013;1.81</td><td rowspan="1" colspan="1">0.520</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">I&#x02013;II</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">III&#x02013;IV</td><td rowspan="1" colspan="1">142</td><td rowspan="1" colspan="1">11.32</td><td rowspan="1" colspan="1">4.14&#x02013;30.96</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">9.42</td><td rowspan="1" colspan="1">2.94&#x02013;30.25</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">ER (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;199)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">74</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">125</td><td rowspan="1" colspan="1">0.70</td><td rowspan="1" colspan="1">0.45&#x02013;1.10</td><td rowspan="1" colspan="1">0.126</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;199)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">93</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">106</td><td rowspan="1" colspan="1">0.72</td><td rowspan="1" colspan="1">0.46&#x02013;1.12</td><td rowspan="1" colspan="1">0.149</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">HER2 (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;196)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">136</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">1.88</td><td rowspan="1" colspan="1">1.19&#x02013;2.95</td><td rowspan="1" colspan="1">0.006</td><td rowspan="1" colspan="1">2.05</td><td rowspan="1" colspan="1">1.17&#x02013;3.56</td><td rowspan="1" colspan="1">0.011</td></tr><tr><td rowspan="1" colspan="1">NLR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.995</td><td rowspan="1" colspan="1">69</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.995</td><td rowspan="1" colspan="1">133</td><td rowspan="1" colspan="1">1.45</td><td rowspan="1" colspan="1">0.89&#x02013;2.34</td><td rowspan="1" colspan="1">0.130</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PLR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;145.5</td><td rowspan="1" colspan="1">87</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;145.5</td><td rowspan="1" colspan="1">115</td><td rowspan="1" colspan="1">1.24</td><td rowspan="1" colspan="1">0.79&#x02013;1.93</td><td rowspan="1" colspan="1">0.351</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">LMR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;0.265</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;0.265</td><td rowspan="1" colspan="1">103</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">0.54&#x02013;1.29</td><td rowspan="1" colspan="1">0.410</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SII</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;774.8</td><td rowspan="1" colspan="1">111</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;774.8</td><td rowspan="1" colspan="1">91</td><td rowspan="1" colspan="1">1.27</td><td rowspan="1" colspan="1">0.82&#x02013;1.97</td><td rowspan="1" colspan="1">0.287</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SIRI</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.11</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.11</td><td rowspan="1" colspan="1">112</td><td rowspan="1" colspan="1">1.19</td><td rowspan="1" colspan="1">0.77&#x02013;1.86</td><td rowspan="1" colspan="1">0.429</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PIV</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;331.8</td><td rowspan="1" colspan="1">103</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;331.8</td><td rowspan="1" colspan="1">99</td><td rowspan="1" colspan="1">1.20</td><td rowspan="1" colspan="1">0.77&#x02013;1.86</td><td rowspan="1" colspan="1">0.415</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">PNI (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;190)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02265;54.06</td><td rowspan="1" colspan="1">81</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003c;54.06</td><td rowspan="1" colspan="1">109</td><td rowspan="1" colspan="1">1.89</td><td rowspan="1" colspan="1">1.17&#x02013;3.06</td><td rowspan="1" colspan="1">0.009</td><td rowspan="1" colspan="1">1.27</td><td rowspan="1" colspan="1">0.72&#x02013;2.24</td><td rowspan="1" colspan="1">0.402</td></tr><tr><td rowspan="1" colspan="1">CAR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;164)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x02264;1.5</td><td rowspan="1" colspan="1">88</td><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Ref</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td style="padding-left:1pc;" rowspan="1" colspan="1">&#x0003e;1.5</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">2.11</td><td rowspan="1" colspan="1">1.24&#x02013;3.57</td><td rowspan="1" colspan="1">0.005</td><td rowspan="1" colspan="1">2.16</td><td rowspan="1" colspan="1">1.27&#x02013;3.68</td><td rowspan="1" colspan="1">0.005</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-6fn"><p>
<bold>Notes.</bold>
</p></fn><fn id="table-6fn1" fn-type="other"><p>
<def-list id="dl6"><def-item><term> HR</term><def><p>Hazard Ratio</p></def></def-item><def-item><term> CI</term><def><p>confidence interval</p></def></def-item><def-item><term> ER</term><def><p>estrogen receptors</p></def></def-item><def-item><term> PR</term><def><p>progesterone receptors</p></def></def-item><def-item><term> HER2</term><def><p>human epidermal growth factor receptor 2</p></def></def-item><def-item><term> NLR</term><def><p>neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term> PLR</term><def><p>platelet-to-lymphocyte ratio</p></def></def-item><def-item><term> LMR</term><def><p>lymphocyte-to-monocyte ratio</p></def></def-item><def-item><term> SII</term><def><p>systemic immune-inflammation index</p></def></def-item><def-item><term> SIRI</term><def><p>systemic inflammation response index</p></def></def-item><def-item><term> PIV</term><def><p>pan-immune inflammation value</p></def></def-item><def-item><term> PNI</term><def><p>prognostic nutritional index</p></def></def-item><def-item><term> CAR</term><def><p>C-reactive protein-to-albumin ratio</p></def></def-item></def-list>
</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Globally, breast cancer is the most prevalent malignancy in females, with significant variations in survival rates across different regions. The 5-year survival of breast cancer was over 85% in the USA, Canada, European countries, Japan, and South Korea (<xref rid="ref-1" ref-type="bibr">Allemani et al., 2018</xref>). In Asia region, Thailand, India, and Malaysia had low 5-year survival (68.7%, 66.1%, 65%, respectively) (<xref rid="ref-36" ref-type="bibr">Soerjomataram et al., 2023</xref>), but still higher than Indonesia (51%) (<xref rid="ref-35" ref-type="bibr">Sinaga et al., 2018</xref>). The present study reported breast cancer 3-year survival of 65.7%, which is lower than Thailand (71.4%) and Malaysia (73.7%), as well as China (88.7%) and South Korea (93.5%) (<xref rid="ref-36" ref-type="bibr">Soerjomataram et al., 2023</xref>). Compared to high-income and even neighboring countries, low breast cancer survival in Indonesia calls for continuous efforts to improve breast cancer care in Indonesia.</p><p>There is growing evidence that breast cancer progression is significantly influenced by the inflammatory pathway (<xref rid="ref-18" ref-type="bibr">Kaur et al., 2019</xref>). In the inflammatory condition, the synthesis of CRP was increased but the production of albumin was suppressed. A low level of albumin may also reduce the tolerance of systemic anti-cancer treatment. Therefore, long-term elevated CRP and reduced albumin levels were predictors of poor survival (<xref rid="ref-30" ref-type="bibr">Nazha, 2015</xref>). CRP-to-albumin ratio (CAR), a biomarker related to inflammation and nutrition, has been demonstrated as a prognostic factor in various cancers including colorectal cancer (<xref rid="ref-32" ref-type="bibr">Ruan et al., 2023b</xref>), gastric cancer (<xref rid="ref-33" ref-type="bibr">Sakai et al., 2020</xref>), pancreatic cancer (<xref rid="ref-10" ref-type="bibr">Fujiwara et al., 2018</xref>), esophageal cancer (<xref rid="ref-15" ref-type="bibr">Ishibashi et al., 2018</xref>), and ovarian cancer (<xref rid="ref-23" ref-type="bibr">Komura et al., 2021</xref>). However, there are few studies on CAR in breast cancer, highlighting the clinical importance of this present study. This study revealed CAR as a prognostic factor in breast cancer patients receiving first-line chemotherapy. It was observed that a high CAR was correlated with poor DFS and OS, aligning with findings from previous studies (<xref rid="ref-42" ref-type="bibr">Zhou et al., 2019</xref>; <xref rid="ref-26" ref-type="bibr">Liu, Guo &#x00026; Zhang, 2021</xref>; <xref rid="ref-31" ref-type="bibr">Ruan et al., 2023a</xref>).</p><p>The underlying causative association between CAR and breast cancer survival remains unclear but several hypotheses have been suggested. CRP, as the first component of CAR, is a well-known acute-phase protein in response to inflammation, trauma, or tissue damage. Even though breast cancer is rarely characterized by a significant histologic inflammation, CRP level might be moderately risen indicating a low-grade chronic inflammation (<xref rid="ref-3" ref-type="bibr">Asegaonkar et al., 2015</xref>). An inflammatory condition in the breast cancer tumor micro-environment results in pro-tumorigenic and pro-angiogenic response which is associated with disease progression, risk of recurrence, and poor outcome (<xref rid="ref-2" ref-type="bibr">Allin et al., 2011</xref>). The molecular pathway underlying an elevated CRP in inflammatory environments has been reported in breast epithelial cells (<xref rid="ref-20" ref-type="bibr">Kim et al., 2014</xref>). Sphingosine-1-phosphate (S1P) markedly activated CRP transcription, increasing the expression of CRP which is secreted into extracellular space. This S1P-induced CRP expression resulted in the upregulation of matrix metalloproteinase (MMP)-9 through extracellular signal-related kinase (ERKs), reactive oxygen species (ROS), and c-fos. Using a xenograft mice tumor model, S1P-induced CRP expression was demonstrated both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> explaining their role in increasing invasive phenotype in breast cancer cells (<xref rid="ref-20" ref-type="bibr">Kim et al., 2014</xref>; <xref rid="ref-21" ref-type="bibr">Kim, Kim &#x00026; Moon, 2023</xref>).</p><p>At the time of diagnosis, elevated CRP level reflects tumor aggressiveness, such as larger tumor size, more advanced stage, higher grade, or the presence of distant metastasis (<xref rid="ref-2" ref-type="bibr">Allin et al., 2011</xref>; <xref rid="ref-3" ref-type="bibr">Asegaonkar et al., 2015</xref>). An elevated CRP level will result in an elevated CAR value. In our study, we found that the proportion of patients with a high CAR was significantly higher in patients with stage IV compared to stage I&#x02013;III disease. We expected that patients with high CAR at diagnosis are carrying elevated inflammatory levels and more severe breast cancer disease, resulting in more aggressive chemotherapy regimen consideration and requiring close attention to prevent poor survival.</p><p>The second component of CAR is albumin. In addition to evaluating patient&#x02019;s nutritional status, serum albumin level might be an indicator that links to disease outcomes in many cancer types including breast cancer. The mechanism by which albumin level might impact cancer survival is expected due to its essential physiologic functions, such as maintaining plasma oncotic pressure, lowering pro-inflammatory fatty acids through its binding effect, and exerting antioxidant activity by scavenging ROS and limiting ROS production. These mechanisms suggest that albumin may inhibit tumor progression, thus improving survival (<xref rid="ref-39" ref-type="bibr">Tang, Li &#x00026; Sun, 2024</xref>). A previous study on breast cancer cell line, MCF-7, demonstrated that albumin may affect cell proliferation by modulating the activation of autocrine growth regulatory factors (<xref rid="ref-24" ref-type="bibr">Laursen, Briand &#x00026; Lykkesfeldt, 1990</xref>). However, despite several hypotheses mentioned above, the underlying biological link between elevated CAR and poor survival remains unexplored, warranting studies on chronic inflammation, hypoalbuminemia, and tumor aggressiveness.</p><p>Our observation on the significant role of CAR in DFS supported previous studies enrolling non-metastatic breast cancer in China (<xref rid="ref-42" ref-type="bibr">Zhou et al., 2019</xref>; <xref rid="ref-26" ref-type="bibr">Liu, Guo &#x00026; Zhang, 2021</xref>). <xref rid="ref-42" ref-type="bibr">Zhou et&#x000a0;al. (2019)</xref> included 200 resectable cases and reported a significantly reduced 5-year DFS among patients with high CAR compared to low CAR (59.8% <italic toggle="yes">vs</italic> 79.2%). Though these results are in line with our findings, the DFS rates are better than ours, in accordance with the aforementioned epidemiological difference. <xref rid="ref-26" ref-type="bibr">Liu, Guo &#x00026; Zhang (2021)</xref> included 199 patients with stage I-III luminal B breast cancer and reported that high CAR was correlated with unfavorable DFS with a higher hazard when compared to that of <xref rid="ref-42" ref-type="bibr">Zhou et&#x000a0;al. (2019)</xref> and ours (HR 4.35 <italic toggle="yes">vs</italic> HR 2.22 and HR 2.10). This might be due to the different numbers of variables included in the multivariate analysis, where <xref rid="ref-26" ref-type="bibr">Liu, Guo &#x00026; Zhang (2021)</xref> was the highest. A more complex model with a limited sample size can lead to overfitting (<xref rid="ref-4" ref-type="bibr">Babyak, 2004</xref>). In terms of OS, our findings were also comparable to previous report recruiting 514 patients with breast cancer (HR 2.56) (<xref rid="ref-31" ref-type="bibr">Ruan et al., 2023a</xref>).</p><p>Our study demonstrating no significant association between high CAR and poor PFS supported previous observation in metastatic breast cancer (<xref rid="ref-19" ref-type="bibr">Kayikciouglu &#x00026; Onder, 2022</xref>). However, there are conflicting findings on the prognostic role of CAR for PFS among other cancers. A study in 90 metastatic colorectal cancer cases showed no difference in 5-year relapse-free survival among such patients having high and low CAR (<xref rid="ref-16" ref-type="bibr">Ishii et al., 2022</xref>). On the contrary, <xref rid="ref-22" ref-type="bibr">Kim et&#x000a0;al. (2020)</xref> found that high CAR was significantly associated with shorter PFS (HR 1.48, 95% CI [1.17&#x02013;1.88], <italic toggle="yes">P</italic>&#x000a0;&#x0003c;&#x000a0;0.001) in unresectable pancreatic cancer patients receiving palliative chemotherapy. <xref rid="ref-22" ref-type="bibr">Kim et al. (2020)</xref> used a markedly higher CAR cut-off compared to our study (3.85 <italic toggle="yes">vs</italic> 1.50). In addition, the median follow-up time from these studies was different, 46&#x02013;48 months in breast cancer (<xref rid="ref-19" ref-type="bibr">Kayikciouglu &#x00026; Onder, 2022</xref>), 44 months in colorectal cancer (<xref rid="ref-16" ref-type="bibr">Ishii et al., 2022</xref>), and 7 months in pancreatic cancer (<xref rid="ref-22" ref-type="bibr">Kim et al., 2020</xref>). The differences in the cut-off value for CAR, the selection of study subjects, and the follow-up time might explain these conflicting findings. Thus, further investigation is required to address this discrepancy.</p><p>Besides CAR, our study also showed that age, stage, and HER2 status were significant prognostic parameters in breast cancer. Advanced age and stage are the established and prominent prognostic factors in breast cancer survival, both at global and national levels (<xref rid="ref-29" ref-type="bibr">Mursyidah, Ashariati &#x00026; Kusumastuti, 2019</xref>; <xref rid="ref-9" ref-type="bibr">Fernandes et al., 2023</xref>). This study reported that HER2 status was significantly associated with poor DFS and OS. HER2 positivity is well known to link to increased brain metastasis, disease recurrence, and mortality risk contributing to worse survival (<xref rid="ref-17" ref-type="bibr">Kang et al., 2023</xref>). Moreover, vast majority of our patients do not have access to anti-HER2 antibody such as trastuzumab because the drug is limitedly covered by the national insurance that supports almost all of our patients (<xref rid="ref-28" ref-type="bibr">Menteri Kesehatan Republik Indonesia, 2018</xref>).</p><p>The measurements of CRP and albumin are readily available, easy to measure, and comparably cheap. In addition, CAR has straightforward calculation and a simple cut-off. Thus, incorporating CAR assessment in routine practice provides additional information for oncologists to identify patients at risk of poorer prognosis and holds the potential to offer more personalized treatment planning including chemotherapy regimen adjustment, frequent monitoring to detect early signs of recurrence, and addressing inflammation or nutritional problems, to prolong survival.</p><p>This is the first study in Indonesia to investigate the prognostic significance of inflammatory and nutritional biomarkers, particularly CAR, in patients with stage I&#x02013;IV breast cancer receiving chemotherapy. Previous studies recruited selective breast cancer patients (<xref rid="ref-42" ref-type="bibr">Zhou et al., 2019</xref>; <xref rid="ref-26" ref-type="bibr">Liu, Guo &#x00026; Zhang, 2021</xref>; <xref rid="ref-19" ref-type="bibr">Kayikciouglu &#x00026; Onder, 2022</xref>) while our study included patients with stage I&#x02013;IV to cover various patients&#x02019; characteristics and yielded findings with broader applicability. This study also analyzed three survival outcomes including DFS, PFS, and OS, representing breast cancer recurrence, disease progression, and mortality. We compared predictive value among several well-known and comparably novel inflammatory and nutritional biomarkers, including NLR, PLR, LMR, SII, SIRI, PIV, PNI, and CAR, which were measured after surgery and before chemotherapy. <xref rid="ref-43" ref-type="bibr">Zhou et&#x000a0;al. (2018)</xref> investigated the predictive values of inflammatory biomarkers before and after tumor resection in colorectal cancer patients. The post-surgery inflammatory biomarkers and their dynamic changes, particularly neutrophil and monocyte-to-lymphocyte ratio (NMLR), SII, and CAR were prognostic predictors of colorectal cancer. Inflammation from the surgical wound healing process ceased one-month post-surgical procedure. Thus, it was expected that there would be no surgery-related disruptions expressed in inflammatory biomarkers. Consequently, it is essential and practical to assess inflammatory biomarkers post-surgery.</p><p>There are several limitations worth noting in the present study. First, this study was a single-centre study with a limited sample size. Findings from a single Indonesian population may not apply broadly, thus a multicentric study would enhance applicability. Second, we generated and used specific cut-off values of inflammation and nutritional biomarkers which are study-specific. Its universal applicability across populations and cancer types warrants further validation study. These conditions demanded cautious interpretation and implementation for patients with different clinicopathological characteristics. Hence, further prospective studies are warranted to validate our findings.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>CAR was demonstrated as a promising prognostic marker in stage I&#x02013;IV breast cancer patients receiving chemotherapy. Among other investigated inflammatory and nutritional biomarkers, CAR showed the greatest discriminating ability. Based on our results, a high CAR (CAR&#x000a0;&#x0003e;&#x000a0;1.5) at diagnosis may serve as a tool to identify patients at risk of unfavorable DFS and OS. This approach can guide personalized treatment planning including chemotherapy regimen adjustment, frequent monitoring to detect early signs of recurrence, and addressing inflammation or nutritional problems.</p></sec><sec sec-type="supplementary-material" id="supplemental-information"><title> Supplemental Information</title><supplementary-material id="supp-1" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19319/supp-1</object-id><label>Supplemental Information 1</label><caption><title>Raw data</title><p>The clinical, pathological, biomarkers, survival, and follow up duration data. The raw data consists of both numeric and categorical value.</p></caption><media xlink:href="peerj-13-19319-s001.xlsx"/></supplementary-material><supplementary-material id="supp-2" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19319/supp-2</object-id><label>Supplemental Information 2</label><caption><title>Kaplan-Meier curves for 3-year disease-free survival based on inflammatory and nutritional biomarkers</title><p>(A) Neutrophil-to-lymphocyte ratio (NLR). (B) Platelet-to-lymphocyte ratio (PLR). (C) Lymphocyte-to-monocyte ratio (LMR). (D) Systemic immune-inflammation index (SII). (E) Systemic inflammation response index (SIRI). (F) Pan-immune inflammation value (PIV). (G) Prognostic nutritional index (PNI).</p></caption><media xlink:href="peerj-13-19319-s002.png"/></supplementary-material><supplementary-material id="supp-3" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19319/supp-3</object-id><label>Supplemental Information 3</label><caption><title>Kaplan-Meier curves for 3-year progression-free survival based on inflammatory and nutritional biomarkers</title><p>(A) Neutrophil-to-lymphocyte ratio (NLR). (B) Platelet-to-lymphocyte ratio (PLR). (C) Lymphocyte-to-monocyte ratio (LMR). (D) Systemic immune-inflammation index (SII). (E) Systemic inflammation response index (SIRI). (F) Pan-immune inflammation value (PIV). (G) Prognostic nutritional index (PNI).</p></caption><media xlink:href="peerj-13-19319-s003.png"/></supplementary-material><supplementary-material id="supp-4" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19319/supp-4</object-id><label>Supplemental Information 4</label><caption><title>Kaplan-Meier curves for 3-year overall survival based on inflammatory and nutritional biomarkers</title><p>(A) Neutrophil-to-lymphocyte ratio (NLR). (B) Platelet-to-lymphocyte ratio (PLR). (C) Lymphocyte-to-monocyte ratio (LMR). (D) Systemic immune-inflammation index (SII). (E) Systemic inflammation response index (SIRI). (F) Pan-immune inflammation value (PIV). (G) Prognostic nutritional index (PNI).</p></caption><media xlink:href="peerj-13-19319-s004.png"/></supplementary-material></sec></body><back><ack><p>We gratefully thank Riani Witaningrum, Benedreky Leo, Irfan Haris, Norma Dewi Suryani, Betrix Rifana Kusuma, Refdiana Dewi, F Linda Tri Pramatasari, Efri Kurniawan, and Sumartiningsih for technical assistance.</p></ack><sec sec-type="additional-information"><title>Additional Information and Declarations</title><fn-group content-type="competing-interests"><title>Competing Interests</title><fn id="conflict-1" fn-type="COI-statement"><p>The authors declare there are no competing interests.</p></fn></fn-group><fn-group content-type="author-contributions"><title>Author Contributions</title><fn id="contribution-1" fn-type="con"><p><xref rid="author-1" ref-type="contrib">Susanna Hilda Hutajulu</xref> conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-2" fn-type="con"><p><xref rid="author-2" ref-type="contrib">Yufi Kartika Astari</xref> analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-3" fn-type="con"><p><xref rid="author-3" ref-type="contrib">Meita Ucche</xref> analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-4" fn-type="con"><p><xref rid="author-4" ref-type="contrib">Nyoman Kertia</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-5" fn-type="con"><p><xref rid="author-5" ref-type="contrib">Yanri Wijayanti Subronto</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-6" fn-type="con"><p><xref rid="author-6" ref-type="contrib">Dewi Kartikawati Paramita</xref> analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-7" fn-type="con"><p><xref rid="author-7" ref-type="contrib">Lina Choridah</xref> performed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-8" fn-type="con"><p><xref rid="author-8" ref-type="contrib">Ericko Ekaputra</xref> performed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-9" fn-type="con"><p><xref rid="author-9" ref-type="contrib">Irianiwati Widodo</xref> performed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-10" fn-type="con"><p><xref rid="author-10" ref-type="contrib">Suwardjo Suwardjo</xref> performed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-11" fn-type="con"><p><xref rid="author-11" ref-type="contrib">Mardiah Suci Hardianti</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-12" fn-type="con"><p><xref rid="author-12" ref-type="contrib">Kartika Widayati Taroeno-Hariadi</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-13" fn-type="con"><p><xref rid="author-13" ref-type="contrib">Ibnu Purwanto</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-14" fn-type="con"><p><xref rid="author-14" ref-type="contrib">Johan Kurnianda</xref> conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.</p></fn></fn-group><fn-group content-type="other"><title>Human Ethics</title><fn id="addinfo-1"><p>The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):</p><p>Medical and Health Research and Ethics Committee, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada (reference number: KE/FK/0417/EC/2018).</p></fn></fn-group><fn-group content-type="other"><title>Data Availability</title><fn id="addinfo-2"><p>The following information was supplied regarding data availability:</p><p>The raw data is available in the <xref rid="supplemental-information" ref-type="sec">Supplementary File</xref>.</p></fn></fn-group></sec><ref-list content-type="authoryear"><title>References</title><ref id="ref-1"><label>Allemani et&#x000a0;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allemani</surname><given-names>C</given-names></name>
<name><surname>Matsuda</surname><given-names>T</given-names></name>
<name><surname>Di&#x000a0;Carlo</surname><given-names>V</given-names></name>
<name><surname>Harewood</surname><given-names>R</given-names></name>
<name><surname>Matz</surname><given-names>M</given-names></name>
<name><surname>Nik&#x00161;i&#x00107;</surname><given-names>M</given-names></name>
<name><surname>Bonaventure</surname><given-names>A</given-names></name>
<name><surname>Valkov</surname><given-names>M</given-names></name>
<name><surname>Johnson</surname><given-names>CJ</given-names></name>
<name><surname>Est&#x000e8;ve</surname><given-names>J</given-names></name>
<name><surname>Ogunbiyi</surname><given-names>OJ</given-names></name>
<name><surname>Azevedo E&#x000a0;Silva</surname><given-names>G</given-names></name>
<name><surname>Chen</surname><given-names>WQ</given-names></name>
<name><surname>Eser</surname><given-names>S</given-names></name>
<name><surname>Engholm</surname><given-names>G</given-names></name>
<name><surname>Stiller</surname><given-names>CA</given-names></name>
<name><surname>Monnereau</surname><given-names>A</given-names></name>
<name><surname>Woods</surname><given-names>RR</given-names></name>
<name><surname>Visser</surname><given-names>O</given-names></name>
<name><surname>Lim</surname><given-names>GH</given-names></name>
<name><surname>Aitken</surname><given-names>J</given-names></name>
<name><surname>Weir</surname><given-names>HK</given-names></name>
<name><surname>Coleman</surname><given-names>MP</given-names></name>
<collab>CONCORD Working&#x000a0;Group</collab>
</person-group><year iso-8601-date="2018">2018</year><article-title>Global surveillance of trends in cancer survival 2000&#x02013;14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries</article-title><source>Lancet</source><volume>391</volume><fpage>1023</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)33326-3</pub-id><pub-id pub-id-type="pmid">29395269</pub-id>
</element-citation></ref><ref id="ref-2"><label>Allin et&#x000a0;al. (2011)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allin</surname><given-names>KH</given-names></name>
<name><surname>Nordestgaard</surname><given-names>BG</given-names></name>
<name><surname>Flyger</surname><given-names>H</given-names></name>
<name><surname>Bojesen</surname><given-names>SE</given-names></name>
</person-group><year iso-8601-date="2011">2011</year><article-title>Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study</article-title><source>Breast Cancer Research</source><volume>13</volume><issue>33</issue><fpage>R55</fpage><pub-id pub-id-type="doi">10.1186/bcr2891</pub-id><pub-id pub-id-type="pmid">21639875</pub-id>
</element-citation></ref><ref id="ref-3"><label>Asegaonkar et&#x000a0;al. (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Asegaonkar</surname><given-names>SB</given-names></name>
<name><surname>Asegaonkar</surname><given-names>BN</given-names></name>
<name><surname>Takalkar</surname><given-names>UV</given-names></name>
<name><surname>Advani</surname><given-names>S</given-names></name>
<name><surname>Thorat</surname><given-names>AP</given-names></name>
</person-group><year iso-8601-date="2015">2015</year><article-title>C-reactive protein and breast cancer: new insights from old molecule</article-title><source>International Journal of Breast Cancer</source><volume>2015</volume><elocation-id>145647</elocation-id><pub-id pub-id-type="doi">10.1155/2015/145647</pub-id><pub-id pub-id-type="pmid">26693355</pub-id>
</element-citation></ref><ref id="ref-4"><label>Babyak (2004)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Babyak</surname><given-names>MA</given-names></name>
</person-group><year iso-8601-date="2004">2004</year><article-title>What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models</article-title><source>Psychosomatic Medicine</source><volume>66</volume><fpage>411</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1097/01.psy.0000127692.23278.a9</pub-id><pub-id pub-id-type="pmid">15184705</pub-id>
</element-citation></ref><ref id="ref-5"><label>Balkwill &#x00026; Mantovani (2001)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balkwill</surname><given-names>F</given-names></name>
<name><surname>Mantovani</surname><given-names>A</given-names></name>
</person-group><year iso-8601-date="2001">2001</year><article-title>Inflammation and cancer: back to Virchow?</article-title><source>The Lancet</source><volume>357</volume><issue>9255</issue><fpage>539</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04046-0</pub-id></element-citation></ref><ref id="ref-6"><label>Cheng et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>T</given-names></name>
<name><surname>Yu</surname><given-names>G</given-names></name>
<name><surname>Xie</surname><given-names>L</given-names></name>
<name><surname>Shi</surname><given-names>B</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Prognostic role of the systemic immune-inflammation index and pan-immune inflammation value for outcomes of breast cancer: a systematic review and meta-analysis</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>28</volume><issue>1</issue><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.26355/eurrev_202401_34903</pub-id><pub-id pub-id-type="pmid">38235869</pub-id>
</element-citation></ref><ref id="ref-7"><label>Deanasa, Umar &#x00026; Fitri (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deanasa</surname><given-names>RS</given-names></name>
<name><surname>Umar</surname><given-names>M</given-names></name>
<name><surname>Fitri</surname><given-names>AD</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Overall survival for stage III breast cancer patients at Dr. Mohammad Hoesin General Hospital Palembang and the influencing factors</article-title><source>Indonesian Journal of Cancer</source><volume>16</volume><issue>4</issue><fpage>231</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.33371/ijoc.v16i4.905</pub-id></element-citation></ref><ref id="ref-8"><label>Ferlay et&#x000a0;al. (2024)</label><element-citation publication-type="other"><person-group person-group-type="author">
<name><surname>Ferlay</surname><given-names>J</given-names></name>
<name><surname>Ervik</surname><given-names>M</given-names></name>
<name><surname>Lam</surname><given-names>F</given-names></name>
<name><surname>Laversanne</surname><given-names>M</given-names></name>
<name><surname>Colombet</surname><given-names>M</given-names></name>
<name><surname>Mery</surname><given-names>L</given-names></name>
<name><surname>Pi&#x000f1;eros</surname><given-names>M</given-names></name>
<name><surname>Znaor</surname><given-names>A</given-names></name>
<name><surname>Soerjomataram</surname><given-names>I</given-names></name>
<name><surname>Bray</surname><given-names>F</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Global cancer observatory: cancer today</article-title><uri xlink:href="https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf">https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf</uri><date-in-citation content-type="access-date" iso-8601-date="2024-11-08">8 November 2024</date-in-citation></element-citation></ref><ref id="ref-9"><label>Fernandes et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>JO</given-names></name>
<name><surname>Cardoso-Filho</surname><given-names>C</given-names></name>
<name><surname>Kraft</surname><given-names>MB</given-names></name>
<name><surname>Detoni</surname><given-names>AS</given-names></name>
<name><surname>Duarte</surname><given-names>BN</given-names></name>
<name><surname>Shinzato</surname><given-names>JY</given-names></name>
<name><surname>Vale</surname><given-names>DB</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Differences in breast cancer survival and stage by age in off-target screening groups: a population-based retrospective study</article-title><source>AJOG Global Reports</source><volume>3</volume><issue>2</issue><elocation-id>100208</elocation-id><pub-id pub-id-type="doi">10.1016/j.xagr.2023.100208</pub-id><pub-id pub-id-type="pmid">37213794</pub-id>
</element-citation></ref><ref id="ref-10"><label>Fujiwara et&#x000a0;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujiwara</surname><given-names>Y</given-names></name>
<name><surname>Haruki</surname><given-names>K</given-names></name>
<name><surname>Shiba</surname><given-names>H</given-names></name>
<name><surname>Hamura</surname><given-names>R</given-names></name>
<name><surname>Horiuchi</surname><given-names>T</given-names></name>
<name><surname>Shirai</surname><given-names>Y</given-names></name>
<name><surname>Furukawa</surname><given-names>K</given-names></name>
<name><surname>Gocho</surname><given-names>T</given-names></name>
<name><surname>Yanaga</surname><given-names>K</given-names></name>
</person-group><year iso-8601-date="2018">2018</year><article-title>C-Reactive protein-based prognostic measures are superior at predicting survival compared with peripheral blood cell count-based ones in patients after curative resection for pancreatic cancer</article-title><source>Anticancer Research</source><volume>38</volume><fpage>6491</fpage><lpage>6499</lpage><pub-id pub-id-type="doi">10.21873/anticanres.13013</pub-id><pub-id pub-id-type="pmid">30396977</pub-id>
</element-citation></ref><ref id="ref-11"><label>Galea et&#x000a0;al. (1992)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galea</surname><given-names>MH</given-names></name>
<name><surname>Blamey</surname><given-names>RW</given-names></name>
<name><surname>Elston</surname><given-names>CE</given-names></name>
<name><surname>Ellis</surname><given-names>IO</given-names></name>
</person-group><year iso-8601-date="1992">1992</year><article-title>The Nottingham prognostic index in primary breast cancer</article-title><source>Breast Cancer Research and Treatment</source><volume>22</volume><issue>3</issue><fpage>207</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1007/BF01840834</pub-id><pub-id pub-id-type="pmid">1391987</pub-id>
</element-citation></ref><ref id="ref-12"><label>Goldhirsch et&#x000a0;al. (2005)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldhirsch</surname><given-names>A</given-names></name>
<name><surname>Glick</surname><given-names>JH</given-names></name>
<name><surname>Gelber</surname><given-names>RD</given-names></name>
<name><surname>Coates</surname><given-names>AS</given-names></name>
<name><surname>Th&#x000fc;rlimann</surname><given-names>B</given-names></name>
<name><surname>Senn</surname><given-names>H-J</given-names></name>
</person-group><year iso-8601-date="2005">2005</year><article-title>Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005</article-title><source>Annals of Oncology</source><volume>16</volume><issue>10</issue><fpage>1569</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdi326</pub-id><pub-id pub-id-type="pmid">16148022</pub-id>
</element-citation></ref><ref id="ref-13"><label>Gradishar et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gradishar</surname><given-names>WJ</given-names></name>
<name><surname>Moran</surname><given-names>MS</given-names></name>
<name><surname>Abraham</surname><given-names>J</given-names></name>
<name><surname>Abramson</surname><given-names>V</given-names></name>
<name><surname>Aft</surname><given-names>R</given-names></name>
<name><surname>Agnese</surname><given-names>D</given-names></name>
<name><surname>Allison</surname><given-names>KH</given-names></name>
<name><surname>Anderson</surname><given-names>B</given-names></name>
<name><surname>Bailey</surname><given-names>J</given-names></name>
<name><surname>Burstein</surname><given-names>HJ</given-names></name>
<name><surname>Chen</surname><given-names>N</given-names></name>
<name><surname>Chew</surname><given-names>H</given-names></name>
<name><surname>Dang</surname><given-names>C</given-names></name>
<name><surname>Elias</surname><given-names>AD</given-names></name>
<name><surname>Giordano</surname><given-names>SH</given-names></name>
<name><surname>Goetz</surname><given-names>MP</given-names></name>
<name><surname>Jankowitz</surname><given-names>RC</given-names></name>
<name><surname>Javid</surname><given-names>SH</given-names></name>
<name><surname>Krishnamurthy</surname><given-names>J</given-names></name>
<name><surname>Leitch</surname><given-names>AM</given-names></name>
<name><surname>Lyons</surname><given-names>J</given-names></name>
<name><surname>McCloskey</surname><given-names>S</given-names></name>
<name><surname>McShane</surname><given-names>M</given-names></name>
<name><surname>Mortimer</surname><given-names>J</given-names></name>
<name><surname>Patel</surname><given-names>SA</given-names></name>
<name><surname>Rosenberger</surname><given-names>LH</given-names></name>
<name><surname>Rugo</surname><given-names>HS</given-names></name>
<name><surname>Santa-Maria</surname><given-names>C</given-names></name>
<name><surname>Schneider</surname><given-names>BP</given-names></name>
<name><surname>Smith</surname><given-names>ML</given-names></name>
<name><surname>Soliman</surname><given-names>H</given-names></name>
<name><surname>Stringer-Reasor</surname><given-names>EM</given-names></name>
<name><surname>Telli</surname><given-names>ML</given-names></name>
<name><surname>Wei</surname><given-names>M</given-names></name>
<name><surname>Wisinski</surname><given-names>KB</given-names></name>
<name><surname>Yeung</surname><given-names>KT</given-names></name>
<name><surname>Young</surname><given-names>JS</given-names></name>
<name><surname>Schonfeld</surname><given-names>R</given-names></name>
<name><surname>Kumar</surname><given-names>R</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>22</volume><issue>5</issue><fpage>331</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2024.0035</pub-id><pub-id pub-id-type="pmid">39019058</pub-id>
</element-citation></ref><ref id="ref-14"><label>Hua et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hua</surname><given-names>X</given-names></name>
<name><surname>Long</surname><given-names>Z-Q</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
<name><surname>Deng</surname><given-names>J-P</given-names></name>
<name><surname>He</surname><given-names>Z-Y</given-names></name>
<name><surname>Guo</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>W-W</given-names></name>
<name><surname>Lin</surname><given-names>H-X</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>The value of Prognostic Nutritional Index (PNI) in predicting survival and guiding radiotherapy of patients with T1-2N1 breast cancer</article-title><source>Frontiers in Oncology</source><volume>9</volume><fpage>1562</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.01562</pub-id><pub-id pub-id-type="pmid">32083015</pub-id>
</element-citation></ref><ref id="ref-15"><label>Ishibashi et&#x000a0;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishibashi</surname><given-names>Y</given-names></name>
<name><surname>Tsujimoto</surname><given-names>H</given-names></name>
<name><surname>Hiraki</surname><given-names>S</given-names></name>
<name><surname>Kumano</surname><given-names>I</given-names></name>
<name><surname>Yaguchi</surname><given-names>Y</given-names></name>
<name><surname>Horiguchi</surname><given-names>H</given-names></name>
<name><surname>Nomura</surname><given-names>S</given-names></name>
<name><surname>Ito</surname><given-names>N</given-names></name>
<name><surname>Shinto</surname><given-names>E</given-names></name>
<name><surname>Aosasa</surname><given-names>S</given-names></name>
<name><surname>Yamamoto</surname><given-names>J</given-names></name>
<name><surname>Ueno</surname><given-names>H</given-names></name>
</person-group><year iso-8601-date="2018">2018</year><article-title>Prognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancer</article-title><source>Annals of Surgical Oncology</source><volume>25</volume><issue>11</issue><fpage>3288</fpage><lpage>3299</lpage><pub-id pub-id-type="doi">10.1245/s10434-018-6651-y</pub-id><pub-id pub-id-type="pmid">30019304</pub-id>
</element-citation></ref><ref id="ref-16"><label>Ishii et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishii</surname><given-names>M</given-names></name>
<name><surname>Tominaga</surname><given-names>T</given-names></name>
<name><surname>Nonaka</surname><given-names>T</given-names></name>
<name><surname>Oyama</surname><given-names>S</given-names></name>
<name><surname>Moriyama</surname><given-names>M</given-names></name>
<name><surname>Maruyama</surname><given-names>K</given-names></name>
<name><surname>Sawai</surname><given-names>T</given-names></name>
<name><surname>Nagayasu</surname><given-names>T</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Colon inflammatory index as a useful prognostic marker after R0 resection in patients with colorectal cancer liver metastasis</article-title><source>PLOS ONE</source><volume>17</volume><issue>10</issue><elocation-id>e0273167</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0273167</pub-id><pub-id pub-id-type="pmid">36194563</pub-id>
</element-citation></ref><ref id="ref-17"><label>Kang et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>YJ</given-names></name>
<name><surname>Oh</surname><given-names>SJ</given-names></name>
<name><surname>Bae</surname><given-names>SY</given-names></name>
<name><surname>Kim</surname><given-names>EK</given-names></name>
<name><surname>Lee</surname><given-names>YJ</given-names></name>
<name><surname>Park</surname><given-names>EH</given-names></name>
<name><surname>Jeong</surname><given-names>J</given-names></name>
<name><surname>Park</surname><given-names>HK</given-names></name>
<name><surname>Suh</surname><given-names>YJ</given-names></name>
<name><surname>Kim</surname><given-names>YS</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Predictive biological factors for late survival in patients with HER2-positive breast cancer</article-title><source>Scientific Reports</source><volume>13</volume><issue>1</issue><fpage>11008</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-38200-y</pub-id><pub-id pub-id-type="pmid">37420033</pub-id>
</element-citation></ref><ref id="ref-18"><label>Kaur et&#x000a0;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>RP</given-names></name>
<name><surname>Rubal</surname></name>
<name><surname>Banipal</surname><given-names>RPS</given-names></name>
<name><surname>Vashistha</surname><given-names>R</given-names></name>
<name><surname>Dhiman</surname><given-names>M</given-names></name>
<name><surname>Munshi</surname><given-names>A</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>Association of elevated levels of C-reactive protein with breast cancer, breast cancer subtypes, and poor outcome</article-title><source>Current Problems in Cancer</source><volume>43</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.currproblcancer.2018.05.003</pub-id><pub-id pub-id-type="pmid">29921457</pub-id>
</element-citation></ref><ref id="ref-19"><label>Kayikciouglu &#x00026; Onder (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kayikciouglu</surname><given-names>E</given-names></name>
<name><surname>Onder</surname><given-names>AH</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>The Pan-immune-inflammation value predicts the survival of patients with ER-positive, HER-2-negative metastatic breast cancer treated with CDK4/6 inhibitors</article-title><source>Chronicles of Precision Medical Researchers</source><volume>3</volume><issue>3</issue><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.5281/zenodo.7195780</pub-id></element-citation></ref><ref id="ref-20"><label>Kim et&#x000a0;al. (2014)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>E-S</given-names></name>
<name><surname>Cha</surname><given-names>Y</given-names></name>
<name><surname>Ham</surname><given-names>M</given-names></name>
<name><surname>Jung</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>SG</given-names></name>
<name><surname>Hwang</surname><given-names>S</given-names></name>
<name><surname>Kleemann</surname><given-names>R</given-names></name>
<name><surname>Moon</surname><given-names>A</given-names></name>
</person-group><year iso-8601-date="2014">2014</year><article-title>Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein <italic toggle="yes">via</italic> C/EBP<italic toggle="yes">&#x003b2;</italic> and potentiates breast cancer progression</article-title><source>Oncogene</source><volume>33</volume><issue>27</issue><fpage>3583</fpage><lpage>3593</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.319</pub-id><pub-id pub-id-type="pmid">23955082</pub-id>
</element-citation></ref><ref id="ref-21"><label>Kim, Kim &#x00026; Moon (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>ES</given-names></name>
<name><surname>Kim</surname><given-names>SY</given-names></name>
<name><surname>Moon</surname><given-names>A</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>C-reactive protein signaling pathways in tumor progression</article-title><source>Biomolecules and Therapeutics</source><volume>31</volume><issue>5</issue><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.4062/biomolther.2023.132</pub-id><pub-id pub-id-type="pmid">37562952</pub-id>
</element-citation></ref><ref id="ref-22"><label>Kim et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>HJ</given-names></name>
<name><surname>Lee</surname><given-names>SY</given-names></name>
<name><surname>Kim</surname><given-names>DS</given-names></name>
<name><surname>Kang</surname><given-names>EJ</given-names></name>
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Choi</surname><given-names>YJ</given-names></name>
<name><surname>Oh</surname><given-names>SC</given-names></name>
<name><surname>Seo</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>JS</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy</article-title><source>Korean Journal of Internal Medicine</source><volume>35</volume><issue>1</issue><fpage>172</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.3904/kjim.2018.076</pub-id></element-citation></ref><ref id="ref-23"><label>Komura et&#x000a0;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Komura</surname><given-names>N</given-names></name>
<name><surname>Mabuchi</surname><given-names>S</given-names></name>
<name><surname>Shimura</surname><given-names>K</given-names></name>
<name><surname>Kawano</surname><given-names>M</given-names></name>
<name><surname>Matsumoto</surname><given-names>Y</given-names></name>
<name><surname>Kimura</surname><given-names>T</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>Significance of pretreatment C-reactive protein, albumin, and C-reactive protein to albumin ratio in predicting poor prognosis in epithelial ovarian cancer patients</article-title><source>Nutrition and Cancer</source><volume>73</volume><issue>8</issue><fpage>1357</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1080/01635581.2020.1798479</pub-id><pub-id pub-id-type="pmid">32835520</pub-id>
</element-citation></ref><ref id="ref-24"><label>Laursen, Briand &#x00026; Lykkesfeldt (1990)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laursen</surname><given-names>I</given-names></name>
<name><surname>Briand</surname><given-names>P</given-names></name>
<name><surname>Lykkesfeldt</surname><given-names>AE</given-names></name>
</person-group><year iso-8601-date="1990">1990</year><article-title>Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7</article-title><source>Anticancer Research</source><volume>10</volume><issue>2A</issue><fpage>343</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">2346307</pub-id>
</element-citation></ref><ref id="ref-25"><label>Liu (2012)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2012">2012</year><article-title>Classification accuracy and cut point selection</article-title><source>Statistics in Medicine</source><volume>31</volume><issue>23</issue><fpage>2676</fpage><lpage>2686</lpage><pub-id pub-id-type="doi">10.1002/sim.4509</pub-id><pub-id pub-id-type="pmid">22307964</pub-id>
</element-citation></ref><ref id="ref-26"><label>Liu, Guo &#x00026; Zhang (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Guo</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>Preoperative serum hypersensitive-c-reactive-protein (Hs-CRP) to albumin ratio predicts survival in patients with luminal B subtype breast cancer</article-title><source>OncoTargets and Therapy</source><volume>14</volume><fpage>4137</fpage><lpage>4148</lpage><pub-id pub-id-type="doi">10.2147/OTT.S320111</pub-id><pub-id pub-id-type="pmid">34276217</pub-id>
</element-citation></ref><ref id="ref-27"><label>Matsunaga et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsunaga</surname><given-names>T</given-names></name>
<name><surname>Miyata</surname><given-names>H</given-names></name>
<name><surname>Sugimura</surname><given-names>K</given-names></name>
<name><surname>Motoori</surname><given-names>M</given-names></name>
<name><surname>Asukai</surname><given-names>K</given-names></name>
<name><surname>Yanagimoto</surname><given-names>Y</given-names></name>
<name><surname>Yamamoto</surname><given-names>K</given-names></name>
<name><surname>Akita</surname><given-names>H</given-names></name>
<name><surname>Nishimura</surname><given-names>J</given-names></name>
<name><surname>Wada</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>H</given-names></name>
<name><surname>Yasui</surname><given-names>M</given-names></name>
<name><surname>Omori</surname><given-names>T</given-names></name>
<name><surname>Ohue</surname><given-names>M</given-names></name>
<name><surname>Fujiwara</surname><given-names>Y</given-names></name>
<name><surname>Yano</surname><given-names>M</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>Prognostic significance of c-reactive protein-to-prealbumin ratio in patients with esophageal cancer</article-title><source>Yonago Acta Medica</source><volume>63</volume><issue>1</issue><fpage>8</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.33160/yam.2020.02.002</pub-id><pub-id pub-id-type="pmid">32158328</pub-id>
</element-citation></ref><ref id="ref-28"><label>Menteri Kesehatan Republik&#x000a0;Indonesia (2018)</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Menteri Kesehatan Republik&#x000a0;Indonesia</collab>
</person-group><year iso-8601-date="2018">2018</year><article-title>Peraturan Menteri Kesehatan Republik Indonesia Nomor 22 Tahun 2018 tentang Petunjuk Teknis Restriksi Penggunaan Obat Trastuzumab untuk Kanker Payudara Metastatik pada Pelayanan Jaminan Kesehatan Nasional</article-title><publisher-loc>Jakarta</publisher-loc><publisher-name>Kementerian Kesehatan</publisher-name><fpage>7</fpage><lpage>11</lpage></element-citation></ref><ref id="ref-29"><label>Mursyidah, Ashariati &#x00026; Kusumastuti (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mursyidah</surname><given-names>NI</given-names></name>
<name><surname>Ashariati</surname><given-names>A</given-names></name>
<name><surname>Kusumastuti</surname><given-names>EH</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>Comparison of breast cancer 3-years survival rate based on the pathological stages</article-title><source>JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga</source><volume>10</volume><issue>1</issue><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.20473/juxta.V10I12019.38-43</pub-id></element-citation></ref><ref id="ref-30"><label>Nazha (2015)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nazha</surname><given-names>B</given-names></name>
</person-group><year iso-8601-date="2015">2015</year><article-title>Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate?</article-title><source>World Journal of Gastrointestinal Surgery</source><volume>7</volume><issue>12</issue><fpage>370</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.4240/wjgs.v7.i12.370</pub-id><pub-id pub-id-type="pmid">26730282</pub-id>
</element-citation></ref><ref id="ref-31"><label>Ruan et&#x000a0;al. (2023a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruan</surname><given-names>GT</given-names></name>
<name><surname>Xie</surname><given-names>HL</given-names></name>
<name><surname>Hu</surname><given-names>CL</given-names></name>
<name><surname>Liu</surname><given-names>CA</given-names></name>
<name><surname>Zhang</surname><given-names>HY</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Wang</surname><given-names>ZW</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Ge</surname><given-names>YZ</given-names></name>
<name><surname>Lin</surname><given-names>SQ</given-names></name>
<name><surname>Tang</surname><given-names>M</given-names></name>
<name><surname>Song</surname><given-names>MM</given-names></name>
<name><surname>Zhang</surname><given-names>XW</given-names></name>
<name><surname>Liu</surname><given-names>XY</given-names></name>
<name><surname>Zhang</surname><given-names>KP</given-names></name>
<name><surname>Yang</surname><given-names>M</given-names></name>
<name><surname>Yu</surname><given-names>KY</given-names></name>
<name><surname>Wang</surname><given-names>KH</given-names></name>
<name><surname>Hu</surname><given-names>W</given-names></name>
<name><surname>Deng</surname><given-names>L</given-names></name>
<name><surname>Cong</surname><given-names>MH</given-names></name>
<name><surname>Shi</surname><given-names>HP</given-names></name>
</person-group><year iso-8601-date="2023">2023a</year><article-title>Comprehensive prognostic effects of systemic inflammation and insulin resistance in women with breast cancer with different BMI: a prospective multicenter cohort</article-title><source>Scientific Reports</source><volume>13</volume><fpage>4304</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-31450-w</pub-id><pub-id pub-id-type="pmid">36922575</pub-id>
</element-citation></ref><ref id="ref-32"><label>Ruan et&#x000a0;al. (2023b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruan</surname><given-names>GT</given-names></name>
<name><surname>Xie</surname><given-names>HL</given-names></name>
<name><surname>Yuan</surname><given-names>KT</given-names></name>
<name><surname>Lin</surname><given-names>SQ</given-names></name>
<name><surname>Zhang</surname><given-names>HY</given-names></name>
<name><surname>Liu</surname><given-names>CA</given-names></name>
<name><surname>Shi</surname><given-names>JY</given-names></name>
<name><surname>Ge</surname><given-names>YZ</given-names></name>
<name><surname>Song</surname><given-names>MM</given-names></name>
<name><surname>Hu</surname><given-names>CL</given-names></name>
<name><surname>Zhang</surname><given-names>XW</given-names></name>
<name><surname>Liu</surname><given-names>XY</given-names></name>
<name><surname>Yang</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>KH</given-names></name>
<name><surname>Zheng</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Hu</surname><given-names>W</given-names></name>
<name><surname>Cong</surname><given-names>MH</given-names></name>
<name><surname>Zhu</surname><given-names>LC</given-names></name>
<name><surname>Deng</surname><given-names>L</given-names></name>
<name><surname>Shi</surname><given-names>HP</given-names></name>
</person-group><year iso-8601-date="2023">2023b</year><article-title>Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia</article-title><source>Journal of Cachexia, Sarcopenia and Muscle</source><volume>14</volume><issue>6</issue><fpage>2813</fpage><lpage>2823</lpage><pub-id pub-id-type="doi">10.1002/jcsm.13358</pub-id><pub-id pub-id-type="pmid">37902006</pub-id>
</element-citation></ref><ref id="ref-33"><label>Sakai et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakai</surname><given-names>M</given-names></name>
<name><surname>Sohda</surname><given-names>M</given-names></name>
<name><surname>Saito</surname><given-names>H</given-names></name>
<name><surname>Ubukata</surname><given-names>Y</given-names></name>
<name><surname>Nakazawa</surname><given-names>N</given-names></name>
<name><surname>Kuriyama</surname><given-names>K</given-names></name>
<name><surname>Hara</surname><given-names>K</given-names></name>
<name><surname>Sano</surname><given-names>A</given-names></name>
<name><surname>Ogata</surname><given-names>K</given-names></name>
<name><surname>Yokobori</surname><given-names>T</given-names></name>
<name><surname>Shirabe</surname><given-names>K</given-names></name>
<name><surname>Saeki</surname><given-names>H</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>Comparative analysis of immunoinflammatory and nutritional measures in surgically resected esophageal cancer: a single-center retrospective study</article-title><source>In Vivo</source><volume>34</volume><issue>2</issue><fpage>881</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.21873/invivo.11853</pub-id><pub-id pub-id-type="pmid">32111799</pub-id>
</element-citation></ref><ref id="ref-34"><label>Savioli et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savioli</surname><given-names>F</given-names></name>
<name><surname>Morrow</surname><given-names>ES</given-names></name>
<name><surname>Dolan</surname><given-names>RD</given-names></name>
<name><surname>Romics</surname><given-names>L</given-names></name>
<name><surname>Lannigan</surname><given-names>A</given-names></name>
<name><surname>Edwards</surname><given-names>J</given-names></name>
<name><surname>McMillan</surname><given-names>DC</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis</article-title><source>British Journal of Surgery</source><volume>109</volume><issue>12</issue><fpage>1206</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1093/bjs/znac319</pub-id><pub-id pub-id-type="pmid">36130112</pub-id>
</element-citation></ref><ref id="ref-35"><label>Sinaga et&#x000a0;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sinaga</surname><given-names>ES</given-names></name>
<name><surname>Ahmad</surname><given-names>RA</given-names></name>
<name><surname>Shivalli</surname><given-names>S</given-names></name>
<name><surname>Hutajulu</surname><given-names>SH</given-names></name>
</person-group><year iso-8601-date="2018">2018</year><article-title>Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia</article-title><source>Pan African Medical Journal</source><volume>31</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.11604/pamj.2018.31.163.17284</pub-id><pub-id pub-id-type="pmid">31086616</pub-id>
</element-citation></ref><ref id="ref-36"><label>Soerjomataram et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soerjomataram</surname><given-names>I</given-names></name>
<name><surname>Cabasag</surname><given-names>C</given-names></name>
<name><surname>Bardot</surname><given-names>A</given-names></name>
<name><surname>Fidler-Benaoudia</surname><given-names>MM</given-names></name>
<name><surname>Miranda-Filho</surname><given-names>A</given-names></name>
<name><surname>Ferlay</surname><given-names>J</given-names></name>
<name><surname>Parkin</surname><given-names>DM</given-names></name>
<name><surname>Ranganathan</surname><given-names>R</given-names></name>
<name><surname>Pi&#x000f1;eros</surname><given-names>M</given-names></name>
<name><surname>Znaor</surname><given-names>A</given-names></name>
<name><surname>Mery</surname><given-names>L</given-names></name>
<name><surname>Joko-Fru</surname><given-names>YW</given-names></name>
<name><surname>Dikshit</surname><given-names>R</given-names></name>
<name><surname>Sankaranarayanan</surname><given-names>R</given-names></name>
<name><surname>Swaminathan</surname><given-names>R</given-names></name>
<name><surname>Bray</surname><given-names>F</given-names></name>
<collab>SURVCAN-3&#x000a0;collaborators</collab>
</person-group><year iso-8601-date="2023">2023</year><article-title>Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries</article-title><source>The Lancet Oncology</source><volume>24</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00704-5</pub-id><pub-id pub-id-type="pmid">36603919</pub-id>
</element-citation></ref><ref id="ref-37"><label>Susini, Biglia &#x00026; Bounous (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Susini</surname><given-names>T</given-names></name>
<name><surname>Biglia</surname><given-names>N</given-names></name>
<name><surname>Bounous</surname><given-names>VE</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Prognostic factors research in breast cancer patients: new paths</article-title><source>Cancer</source><volume>14</volume><issue>4</issue><fpage>971</fpage><pub-id pub-id-type="doi">10.3390/cancers14040971</pub-id></element-citation></ref><ref id="ref-38"><label>Suzuki et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>S</given-names></name>
<name><surname>Akiyoshi</surname><given-names>T</given-names></name>
<name><surname>Oba</surname><given-names>K</given-names></name>
<name><surname>Otsuka</surname><given-names>F</given-names></name>
<name><surname>Tominaga</surname><given-names>T</given-names></name>
<name><surname>Nagasaki</surname><given-names>T</given-names></name>
<name><surname>Fukunaga</surname><given-names>Y</given-names></name>
<name><surname>Ueno</surname><given-names>M</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage II/III colon cancer</article-title><source>Annals of Surgical Oncology</source><volume>27</volume><issue>3</issue><fpage>844</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1245/s10434-019-07904-9</pub-id></element-citation></ref><ref id="ref-39"><label>Tang, Li &#x00026; Sun (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Sun</surname><given-names>CR</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Predictive value of serum albumin levels on cancer survival: a prospective cohort study</article-title><source>Frontiers in Oncology</source><volume>14</volume><elocation-id>1323192</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2024.1323192</pub-id><pub-id pub-id-type="pmid">38500655</pub-id>
</element-citation></ref><ref id="ref-40"><label>Xu et&#x000a0;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H</given-names></name>
<name><surname>Ma</surname><given-names>Y</given-names></name>
<name><surname>Deng</surname><given-names>F</given-names></name>
<name><surname>Ju</surname><given-names>W</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
</person-group><year iso-8601-date="2017">2017</year><article-title>The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis</article-title><source>OncoTargets and Therapy</source><volume>10</volume><fpage>3059</fpage><lpage>3070</lpage><pub-id pub-id-type="doi">10.2147/OTT.S137002</pub-id><pub-id pub-id-type="pmid">28790840</pub-id>
</element-citation></ref><ref id="ref-41"><label>Zhang &#x00026; Cheng (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Cheng</surname><given-names>T</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Prognostic and clinicopathological value of systemic inflammation response index (SIRI) in patients with breast cancer: a meta-analysis</article-title><source>Annals of Medicine</source><volume>56</volume><issue>1</issue><elocation-id>2337729</elocation-id><pub-id pub-id-type="doi">10.1080/07853890.2024.2337729</pub-id><pub-id pub-id-type="pmid">38569199</pub-id>
</element-citation></ref><ref id="ref-42"><label>Zhou et&#x000a0;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L</given-names></name>
<name><surname>Ma</surname><given-names>S</given-names></name>
<name><surname>Balde</surname><given-names>AI</given-names></name>
<name><surname>Han</surname><given-names>S</given-names></name>
<name><surname>Cai</surname><given-names>Z</given-names></name>
<name><surname>Li</surname><given-names>Z</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>A retrospective propensity score matched study of the preoperative c-reactive protein to albumin ratio and prognosis in patients with resectable non-metastatic breast cancer</article-title><source>Medical Science Monitor</source><volume>25</volume><fpage>4342</fpage><lpage>4352</lpage><pub-id pub-id-type="doi">10.12659/MSM.913684</pub-id><pub-id pub-id-type="pmid">31182704</pub-id>
</element-citation></ref><ref id="ref-43"><label>Zhou et&#x000a0;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>ZQ</given-names></name>
<name><surname>Pang</surname><given-names>S</given-names></name>
<name><surname>Yu</surname><given-names>XC</given-names></name>
<name><surname>Xue</surname><given-names>Q</given-names></name>
<name><surname>Jiang</surname><given-names>HY</given-names></name>
<name><surname>Liang</surname><given-names>XJ</given-names></name>
<name><surname>Liu</surname><given-names>L</given-names></name>
</person-group><year iso-8601-date="2018">2018</year><article-title>Predictive values of postoperative and dynamic changes of inflammation indexes in survival of patients with resected colorectal cancer</article-title><source>Current Medical Science</source><volume>38</volume><issue>5</issue><fpage>798</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1007/s11596-018-1946-6</pub-id><pub-id pub-id-type="pmid">30341514</pub-id>
</element-citation></ref></ref-list></back></article>